Top

Homer A. Macapinlac, M.D., FACNM

Department of Nuclear Medicine, Division of Diagnostic Imaging

About Dr. Homer A. Macapinlac

Dr. Macapinlac is the James E. Anderson Distinguished Professor in Nuclear Medicine and Chairman of the Department of Nuclear Medicine. He holds a joint appointment in the Department of Experimental Imaging. He joined M. D. Anderson Cancer Center (MDACC) in 2001 as an Associate Professor and Chief, Section of Positron Emission Tomography. Prior to MDACC, he served as clinical director of the Laurent and Alberta Gershel Positron Emission Tomography Center of Memorial Sloan-Kettering Cancer Center, in New York for six years. He completed his residency training in Nuclear Medicine at Memorial-Sloan Kettering Cancer Center, serving as chief resident in the Nuclear Medicine Service. He then completed his Oncologic Imaging and PET fellowship at MSKCC and became chief fellow. Dr. Macapinlac is board certified by the American Board of Nuclear Medicine, with a Certificate of Added Qualification (CAQ) in Nuclear Cardiology. He was also elected as a fellow of the American College of Nuclear Physicians in September 2009.

He is an active committee member of various groups, including the Society of Nuclear Medicine, American College of Nuclear Physicians, Radiological Society of North America, European Association of Nuclear Medicine, American College of Radiology, Academy of Molecular Imaging, ACRIN and American College of Surgeons Oncology Group. He currently serves as President of the Society of Nuclear Medicine PET Center of Excellence. Dr. Macapinlac is also an expert consultant to the International Atomic Energy Agency, a member of the International Association for the Study of Lung Cancer, and recently appointed as an International Visiting Professor for the Radiological Society of North America.

Primary Appointment

Professor (Joint appointment), Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Endowed Distinguished Professor James E. Anderson Distinguished Professor of Nuclear Medicine, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

James E. Anderson Distinguished Professor of Nuclear Medicine, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Novel tracers for oncologic imaging
Novel therapies for cancer using radionuclides

Education & Training

Degree-Granting Education

1983	University of the East, Ramon Magsaysay Memorial Medical Center, Quezon City, PH, MD
1979	University of the Philippines, Quezon City, PH, Biology, BS

Postgraduate Training

2021-2022	LEADing Teams Core Cohort, The University of Texas MD Anderson Cancer Center, Houston, Texas
1992-1994	Clinical Fellowship, Positron Emission Tomography and Nuclear Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
1991-1992	Chief Resident, Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
1989-1991	Resident, Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
1988-1989	Chief Resident, Anatomic and Surgical Pathology, New York Medical College, Metropolitan-Lincoln Hospitals, New York, New York
1987-1988	Clinical Residency, Anatomic and Surgical Pathology, New York Medical College, Metropolitan-Lincoln Hospitals, New York, New York
1985-1987	Research Fellowship, Nuclear Medicine & MRI, University of California School of Medicine, San Francisco, California
1984-1985	Clinical Internship, Family Medicine, Philippine Ministry of Health-Rural Health Practice Program, Quezon City
1983-1984	Clinical Internship, University of the East, Quezon City

Licenses & Certifications

2006	Controlled Substance Registration Certificate (Federal)
2001	Certification Board of Nuclear Cardiology
2001	Texas Medical Board
1991	American Board of Nuclear Medicine
1987	New York Board of Medical Examiners

Experience & Service

Faculty Academic Appointments

Professor, Department of Experimental Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2013

Associate Professor, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2007

Associate Professor, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2007

Associate Professor, Department of Nuclear Medicine, Cornell University Medical College, New York, NY, 2000 - 2001

Associate Professor, Department of Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 2000 - 2001

Assistant Professor, Department of Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 1994 - 2000

Assistant Professor, Department of Nuclear Medicine, Cornell University Medical College, New York, NY, 1994 - 2000

Administrative Appointments/Responsibilities

Department Chair, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2023

Department Chair ad interim, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2006

Section Chief, Positron Emission Tomography (PET), Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2006

Deputy Department Chair, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2005

Section Chief, Clinical Nuclear Medicine, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2006

Residency Program Associate Director, Department of Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 1996 - 1998

Lymphoma Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY, 1995 - 2001

Head & Neck Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY, 1995 - 2001

Thoracic Disease management Team, Memorial Sloan Kettering Cancer Center, New York, NY, 1995 - 2001

CNS Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY, 1995 - 2001

Clinical Director, Department of Laurent & Alberta Gerschel PET Facility, Memorial Sloan Kettering Cancer Center, New York, NY, 1994 - 2001

Other Professional Positions

Consultant, Cardinal Health, Dublin, OH, 2003 - 2009

Consultant, GE Healthcare, Inc, Milwaukee, WI, 2001 - 2009

Expert Consultant, International Atomic Energy Agency, Vienna, Austria, 2000 - Present

Extramural Institutional Committee Activities

Selection Committee Member, Making Cancer History Patient Care Award, The University of Texas MD Anderson Cancer Center, 2015 - Present

Member, DI Faculty Functional Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, DI Clinical Finance Functional Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, DI Research Series Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present

Member, CABI Research Operations Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present

Member, CABI Executive Steering Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present

Member, EDI CIPRIT Grant Internal Advisory Board, The University of Texas MD Anderson Cancer Center, 2010 - 2010

Member, Medical Physics Task Force - Chair: Dr. Raymond Sawaya, The University of Texas MD Anderson Cancer Center, 2010 - 2010

Member, RIS Executive Steering Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2013

Member, Experimental Diagnostic Imaging Medical Director Search Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2010

Member, Search Committee for the Experimental Diagnostic Imaging Section of Cyclotron-Radiochemistry Chief, The University of Texas MD Anderson Cancer Center, 2008 - 2010

Member, Plastic Surgery Policies & Procedures Task Force, The University of Texas MD Anderson Cancer Center, 2007 - 2009

Member, CME Advisory Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2010

Alternate Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2006 - 2012

Member, Diagnostic Radiology Executive Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2008

Member, Radiation Oncology Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2006

Member, UT Houston GSBS Advisory committee, The University of Texas MD Anderson Cancer Center, 2006 - 2007

Member, MDACC/IGR Sister Institution Program, The University of Texas MD Anderson Cancer Center, 2006 - Present

Member, EDI Search Committee, The University of Texas MD Anderson Cancer Center, 2005

Member, PET/CT Q/A & Education, The University of Texas MD Anderson Cancer Center, 2004 - Present

Member, EDI Internal Advisory Board, The University of Texas MD Anderson Cancer Center, 2003 - 2011

Member, Institutional Review Board #2, The University of Texas MD Anderson Cancer Center, 2003 - 2007

Leader, PET Steering Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2005

Member, Diagnostic Imaging Executive Committee, The University of Texas MD Anderson Cancer Center, 2001 - Present

Editorial Activities

Member/Advisor, Honorary Editorial Board, Indian Journal of Nuclear Medicine, 2014

Member of Editorial Review Board, Nuclear Medicine Communications, 2009 - 2012

Member, Editorial Advisory Board, Molecular Imaging Insight, 2007 - Present

Member of Editorial Review Board, European Journal of Nuclear Medicine and Molecular Imaging, 2004 - Present

Member of Editorial Review Board, Clinical Nuclear Medicine, 2000 - Present

Member of Editorial Review Board, Clinical Positron Imaging/Molecular Imaging and Biology, 1997 - Present

Member of Editorial Review Board, Journal of Nuclear Medicine, 1995 - 2000

Honors & Awards

2023	Outstanding Medical Distinguished Alumni Award, The University of the East Ramon Magsaysay College of Medicine Alumni Association
2023	SNMMI PET Center of Excellence Peter Valk Memorial Award, The Society of Nuclear Medicine & Molecular Imaging (SNMMI)
2019	Daniel R. Biello Memorial Lecture 33rd, Washington University
2019	George Taplin Memorial Lecture, Western Region Society of Nuclear Medicine
2016 - 2024	Honorary Fellow - Philippine Society of Nuclear Medicine, Philippine Society of Nuclear Medicine
2014	Howard Kay Memorial Lecture, SNMMI New Haven
2014	Inaugural MIM Software Lectureship in Molecular Imaging
2014	Vikram Sarabhai Oration, SNMMI India
2009 - 2013	Best Doctors in America
2009	President's Distinguished Service Award, Society of Nuclear Medicine
2008 - 2011	Invited Lecturer, International Visiting Professor Program, Radiological Society of North America
2008	Most Outstanding Alumnus in Medical Research, UERM College of Medicine
2007	Top 50 Most Cited Articles in 2007, Journal of Clinical Oncology
2003	Outstanding Educator Award, University of Texas MD Anderson Cancer Center
1994	Outstanding Manuscript Award, Journal of Nuclear Medicine
1991 - 1993	Best Proffered Paper, Society of Nuclear Medicine
1991	Second Prize, Scientific Exhibit, Society of Nuclear Medicine

Professional Memberships

National Institutes of Health

2009 - 2013

National Comprehensive Cancer Network

2008

American Board of Radiology

2007 - Present

Harris County Medical Society

2007 - Present

American College of Radiology

2006 - Present

International Association for the Study of Lung Cancer (IASLC)

2006 - Present

American College of Surgeons Oncology Group

2006 - Present

Texas Medical Association

2006 - Present

Society of Nuclear Medicine Molecular Imaging

2005 - Present

European Association of Nuclear Medicine

2005 - Present

Southwest Chapter of the Society of Nuclear Medicine

2004 - Present

Academy of Molecular Imaging

2003 - Present

American College of Nuclear Physicians

2003 - Present

Radiological Society of North America

1995 - Present

Selected Presentations & Talks

Regional Presentations

2023. Oncologic Imaging and Theranostics Applications. Conference. MD Anderson Cancer Network, US.
2012. Clinical Somatostatin Receptor Imaging. Conference. SW Chapter SNM. Galveston, TX, US.
2007. Early response evaluation in lymphoma with PET/CT. Conference. Texas Radiological Society. The Woodlands, TX, US.
2007. PET/CT: Guide to non-invasive and invasive staging of NSCLC. Conference. Texas Radiological Society. The Woodlands, TX, US.
2007. PET and diagnosis at MD Anderson Cancer Center. Conference. SW Chapter SNM. Ft. Worth, TX, US.
2006. PET/CT: Its use in Lung Cancer. Conference. SW Chapter SNM. The Woodlands, TX, US.

National Presentations

2023. Peter Valk Award Lecture: Advances and Clinical Applications of PET. Invited. SNMMI PET Center of Excellence. Chicago, IL, US.
2023. Oncologic Imaging and Theranostics. Invited. MD Anderson Cancer Network Speaker's Bureau. Houston, TX, US.
2020. Image Interpretation Session: Nuclear Medicine & Musculoskeletal. Conference. 106th Scientific Assembly and Annual Meeting. Virtual, US.
2020. BOOST: Advanced Techniques in Image Guided Therapy: Theranostics. Invited. 106th Scientific Assembly and Annual Meeting. Virtual, US.
2019. BOOST: Advanced Techniques in Image-Guided Therapy. Invited. 105th Scientific Assembly and Annual Meeting. Chicago, IL, US.
2019. Taplin Lecture: Role of Nuclear Medicine in the Multidisciplinary Management of Cancer Patients. Invited. Society of Nuclear Medicine and Molecular Imaging Western Region Annual Meeting. Tucson, AZ, US.
2018. BOOST: Advanced Techniques in Image Guided Therapy. Invited. 104th Scientific Assembly and Annual Meeting. Chicago, IL, US.
2018. Integrating Molecular Imaging into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities. Invited. AUA 2018 Annual Meeting. San Francisco, CA, US.
2018. Parathyroid, Thyroid and Other Emerging Topics in Nuclear Medicine - "Emerging Topics in Nuclear Medicine". Invited. Society of Nuclear Medicine and Molecular Imaging (SNMMI), American College of Nuclear Medicine (ACNM). Orlando, FL, US.
2017. CE32: Patient Centered Imaging - The Changing Role of the Nuclear Medicine Physician. Conference. SNMMI 2017 Annual Meeting. Denver, CO, US.
2017. CAT6: Quality in Nuclear Medicine Navigating the Shift from Volume to Value - Team Based Nuclear Medicine; Best Practices. Invited. SNMMI 2017 Annual Meeting. Denver, CO, US.
2017. Progress Update: Prostate Cancer Imaging and Treatment. Invited. APhA 2017 Annual Meeting: Making an Impact In Patient Care. San Francisco, CA, US.
2017. Parathyroid, Thyroid and Other Emerging Topics in Nuclear Medicine - Emergint Topics in Nuclear Medicine. Invited. SNMMI Mid-Winter Meeting. Lake Buena Vista, FL, US.
2016. Moderator: Poster Discussions - Molecular Imaging. Conference. 2016 RSNA Scientific Assembly and Meeting. Chicago, IL, US.
2016. Refresher Course: Imaging of Osteosarcoma using Bone Scintigraphy, Sodium Fluoride- 18- PET/CT and Fluoro- 18-Deoxyglucose PET/CT - Evaluation of Treatment Response in a Phase I Trial with Radium-223 Therapy. Conference. 2016 RSNA Scientific Assembly and Meeting. Chicago, IL, US.
2016. Intravenous and oral contrast in FDG PET/CT studies for oncology. Invited. IAEA Regional Training Course. Seoul.
2016. FDG PET-CT in Lung Cancer Education Session - Moderator. Invited. SNMMI 2016 Annual Meeting. San Diego, CA, US.
2016. Evolving Practice of PET/CT in Multi-Disciplinary Care of Cancer Patients. Invited. Educational Symposia. Orlando, FL, US.
2016. Fundamentals of FDG PET/CT in Lung Cancer. Invited. Educational Symposia. Orlando, FL, US.
2016. Fundamentals of FDG PET/CT in Lymphoma. Invited. Educational Symposia. Orlando, FL, US.
2015. Bladder, the Forgotten Organ: Role of CT, MRI, and PET in Diagnosis, Staging, and Surveillance of Cancer. Invited. 2015 RSNA Scientific Assembly and Meeting. Chicago, IL, US.
2015. Moderator: Poster Discussions - Molecular Imaging. Invited. 2015 RSNA Scientific Assembly and Meeting. Chicago, IL, US.
2015. The Evolving Role of Clinical Molecular Imaging in Multi-Disciplinary Cancer Care. Invited. British Nuclear Medicine Society. Brighton.
2015. Appropriate Use of NM and MI in Cancer Screening and Diagnosis. Invited. ACNM/SNMMI Annual Meeting. San Antonio, TX, US.
2014. Bladder, the Forgotten Organ: Role of CT, MRI, and PET in Diagnosis, Staging, and Surveillance of Cancer. Invited. Radiological Society of North America. Chicago, IL, US.
2014. PET novel tracers. Invited. Northeast Regional Meeting, Greater NY and New England Chapters, SNMMI. Stamford, CT, US.
2014. Clinical applications of SPECT/CT in oncology. Invited. Northeast Regional Meeting, Greater NY and New England Chapters, SNMMI. Stamford, CT, US.
2014. Clinical SPECT/CT: Technology & Reconstruction. Invited. Society of Nuclear Medicine & Molecular Imaging. Palm Springs, CA, US.
2013. Bladder, the Forgotten Organ: Role of PET in Diagnosis, Staging, and Surveillance of Bladder Cancer. Invited. Radiological Society of North America. Chicago, IL, US.
2013. Future Direction of PET/CT and PET/MR. Invited. 11th Annual 2013 PET-CT Imaging. Orlando, FL, US.
2013. Clinical Variance of Quantitative Response Evaluation. Invited. 11th Annual 2013 PET-CT Imaging. Orlando, FL, US.
2013. SPECT"acular" CT for Diagnosis and Staging in Oncology. Invited. Clinical Nuclear Medicine 2013. Orlando, FL, US.
2013. Imaging Algorithm for the Detection of Osseous Metastases. Invited. Clinical Nuclear Medicine 2013. Orlando, FL, US.
2012. Clinical Radionuclide Imaging Agents for Musculoskeletal Malignancies. Invited. Radiological Society of North America. Chicago, IL, US.
2012. Functional Imaging of Molecular Targets with Novel Tracers. Invited. Radiological Society of North America. Chicago, IL, US.
2012. Lung Nodule Characterization: PET. Invited. Radiological Society of North America. Chicago, IL, US.
2012. Biologic Molecular Imaging. Invited. ARS's 94th Annual Meeting. Las Vegas, NV, US.
2011. Clinical Radionuclide Imaging Agents for Musculoskeletal Malignancies. Invited. Radiological Society of North America. Chicago, IL, US.
2011. Review of TNM Staging of Non-Small Cell Lung Cancer. Invited. Society of Nuclear Medicine 57th Annual Meeting. San Antonio, TX, US.
2011. SPECTacular CT - No Turning Back Once Your Try It. Invited. Society of Nuclear Medicine 57th Annual Meeting. San Antonio, TX, US.
2011. PET/CT of Lung Cancer. Invited. Society of Nuclear Medicine 57th Annual Meeting. San Antonio, TX, US.
2011. Do We Need Guidelines for Reporting FDG/PET Scans in Oncology?. Invited. PET Imaging 2011. Lake Buena Vista, FL, US.
2011. Whole Body MR versus Whole Body PET-CT: From Head to Toe, Now Head to Head. Invited. PET Imaging 2011. Lake Buena Vista, FL, US.
2011. Clinical FDG/PET Imaging. Invited. PET Imaging 2011. Lake Buena Vista, FL, US.
2011. Imaging Algorithm for Detection of Osseous Metastases. Invited. Clinical Nuclear Medicine 2011. Lake Buena Vista, FL, US.
2011. PET/CT Staging and Treatment Response. Invited. 2011 Cancer Imaging & Radiation Therapy Symposium. Atlanta, GA, US.
2011. Keynote Address: PET/CT and Cutaneous Tumors. Invited. ACMS 2011 Annual Meeting. Las Vegas, NV, US.
2010. Current & Future Trends in Clinical Molecular Imaging of Lung Cancer. Invited. Radiological Society of North America. Chicago, IL, US.
2010. Clinical Radionuclide Imaging Agents for Musculoskeletal Malignancies. Invited. Radiological Society of North America. Chicago, IL, US.
2010. Future Directions of PET/CT. Invited. 3rd Annual Symposium on Cancer Management and Role of PET/CT. Bretton Woods, NH, US.
2010. Monitoring Treatment Response with PET/CT in Clinical Practice. Invited. 3rd Annual Symposium on Cancer Management and Role of PET/CT. Bretton Woods, NH, US.
2010. Elements of PET/CT Reporting - SNM PET Center of Excellence. Invited. 3rd Annual Symposium on Cancer Management and Role of PET/CT. Bretton Woods, NH, US.
2010. Strengths and Weaknesses of PET/CT in GU/GYN Applications. Invited. 3rd Annual Symposium on Cancer Management and Role of PET/CT. Bretton Woods, NH, US.
2010. When does PET/CT add value to clinical practice in oncology. Invited. Cardinal Health. Houston, TX, US.
2010. Challenges in PET/CT of the Chest. Invited. Society of Nuclear Medicine Mid-Winter. Albuquerque, NM, US.
2009. Special Focus Session: "SUVs in PET Imaging: Useful Tool or Silly Useless Value?". Invited. Radiological Society of North America. Chicago, IL, US.
2009. PET/CT Imaging of Thyroid Cancer. Invited. 3rd Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Santa Fe, NM, US.
2009. Introduction to FDG PET/CT. Invited. AAO-HNS Annual Meeting. San Diego, CA, US.
2009. Application of positron emission tomography (PET) in neurological disorders. Invited. UERMMMC Annual Meeting. New York, NY, US.
2009. WEBCAST: PET/CT in malignant melanoma - How to make a clinically relevant report. Invited. Academy of Molecular Imaging. Culver City, CA, US.
2009. FDG PET/CT: A roadmap for invasive staging of NSCLC. Invited. 7th Annual PET/CT Imaging Symposium. Las Vegas, NV, US.
2009. FDG PET/CT imaging protocols in oncology. Invited. 7th Annual PET/CT Imaging Symposium. Las Vegas, NV, US.
2008. Keynote Speaker: Silly Useless Value or Simple Useful Valuable. Invited. Radiological Society of North America. Chicago, IL, US.
2008. PET/CT applications in thoracic imaging. Invited. A Comprehensive Course in Oncologic Imaging: PET/CT, MDCT, and MR for Radiologists, Oncologists and Surgeons. Philadelphia, PA, US.
2008. PET/CT Imaging: Oncology. Invited. 2008 Symposium on Emerging Trends in Advanced Diagnostic Imaging. Chicago, IL, US.
2008. PET/CT in head & neck cancer: Controversies & challenges. Invited. American Academy of Otolaryngology-Head & Neck Surgery Annual Meeting. Chicago, IL, US.
2008. Diagnostic clinical applications of PET. Invited. American Association of Medical Physicists. Houston, TX, US.
2008. PET/CT in Mesothelioma. Invited. American Roentgen Ray Society. Washington, DC, US.
2008. Breath Holding and Gating. Invited. Best Practices in PET/CT Symposium. Sonoma, CA, US.
2008. PET/CT Imaging of Lung Cancer. Invited. American College of Nuclear Medicine. Lake Buena Vista, FL, US.
2008. PET/CT Imaging of Esophageal Cancer. Invited. American College of Nuclear Medicine. Lake Buena Vista, FL, US.
2008. Recent Developments in Lung Cancer Imaging: PET. Invited. 5th Annual Winter Lung Conference. Sunny Isles, FL, US.
2008. Case Study Conclusion and Panel Discussion. Invited. 5th Annual Winter Lung Cancer Conference. Sunny Isles, FL, US.
2008. PET/CT in Radiation Therapy Planning. Invited. American College of Radiology. Palm Springs, CA, US.
2008. Challenging Cases: Read with the Experts. Invited. American College of Radiology. Palm Springs, CA, US.
2007. Utility of PET/CT in Radiotherapy Imaging Planning. Invited. National DI Imaging Symposium. Orlando, FL, US.
2007. PET in Lymphoma. Invited. National DI Imaging Symposium. Orlando, FL, US.
2007. Molecular Imaging in Oncology: Radiation Treatment Planning. Invited. Radiological Society of North America Annual Meeting. Chicago, IL, US.
2007. Molecular Imaging Advances in Oncology. Invited. Radiological Society of North America Annual Meeting. Chicago, IL, US.
2007. PET of the Thorax: Radiation Treatment Planning. Invited. Radiological Society of North America Annual Meeting. Chicago, IL, US.
2007. PET/CT Imaging of Thyroid Cancer. Invited. 2nd Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Santa Fe, NM, US.
2007. PET & Diagnosis at MD Anderson Cancer Center. Invited. Florida Pharmacy Association. Orlando, FL, US.
2007. Imaging Protocols. Invited. Joint Molecular Imaging Conference 2007. Providence, RI, US.
2007. FDG PET/CT of Esophageal Cancer. Invited. American Roentgen Ray Society. Orlando, FL, US.
2007. PET/CT for Rx Planning. Invited. 5th Annual PET/CT Imaging Symposium. Las Vegas, NV, US.
2007. FDG PET/CT Imaging Protocols. Invited. 5th Annual PET/CT Imaging Symposium. Las Vegas, NV, US.
2007. Women's Imaging & Lymphoma: Lymphoma. Invited. Oncologic Imaging for the Practicing Radiologist: PET & PET/CT. Charleston, SC, US.
2007. The Brain & Beyond: Melanoma. Invited. Oncologic Imaging for the Practicing Radiologist: PET & PET/CT. Charleston, SC, US.
2007. PET/CT Nuts, Bolts, Artifacts. Invited. Big Sky Radiology Conference. Big Sky, MT, US.
2007. PET/CT in Thoracic Imaging. Invited. Big Sky Radiology Conference. Big Sky, MT, US.
2007. PET/CT in Lymphoma and Melanoma. Invited. Big Sky Radiology Conference. Big Sky, MT, US.
2007. PET/CT in Cervical and Breast Cancer. Invited. Big Sky Radiology Conference. Big Sky, MT, US.
2007. Oncology: Paradigm Shift in Radiologist's Role. Invited. American College of Radiology. Boca Raton, FL, US.
2007. PET/CT in Head and Neck Cancers. Invited. American College of Radiology. Boca Raton, FL, US.
2007. PET/CT of GI Malignancy. Invited. American College of Radiology. Boca Raton, FL, US.
2007. Standardization of PET/CT Imaging Protocols for Cancer. Invited. Academy of Molecular Imaging. South Beach, FL, US.
2006. PET Imaging Follow-up of Ablative Techniques in NSCLS. Invited. Radiological Society of North America Annual Meeting. Chicago, IL, US.
2006. PET in GU malignancy. Invited. Radiological Society of North America Annual Meeting. Chicago, IL, US.
2006. Presiding Officer: Nuclear Medicine - PET/CT and Lymphoma. Invited. Radiological Society of North America Annual Meeting. Chicago, IL, US.
2006. PET/CT: Head and Neck. Invited. A Comprehensive Course in Oncologic Imaging for the Practicing Radiologist. Washington, DC, US.
2006. PET/CT: In GYN Tumors and Melanoma. Invited. A Comprehensive Course in Oncologic Imaging for the Practicing Radiologist. Washington, DC, US.
2006. Read with the Experts: Correlative PET Imaging in Cancer with Other Cross-sectional Imaging. Invited. Society of Nuclear Medicine Annual Meeting. San Diego, CA, US.
2006. PET/CT in Radiation Treatment Panning. Invited. Society of Nuclear Medicine Annual Meeting. San Diego, CA, US.
2006. Paradigm shift in the use of PET to PET/CT in lung cancer. Invited. American College of Radiology Arkansas Chapter. Little Rock, AR, US.
2006. FDG PET in Radiotherapy Planning. Invited. Texas Radiological Society 93rd Annual Scientific Meeting. Austin, TX, US.
2006. Pulmonary Function Assessment. Invited. Texas Radiological Society 93rd Annual Scientific Meeting. Austin, TX, US.
2006. PET & Cervical Cancer. Invited. SW Chapter of the Society of Nuclear Medicine. Albuquerque, NM, US.
2006. CT of the Abdomen - Fundamentals. Invited. American College of Nuclear Medicine. San Antonio, TX, US.
2006. PET/CT of the Abdomen. Invited. American College of Nuclear Medicine. San Antonio, TX, US.
2006. Clinical Indications in PET with 18FDG Oncology. Invited. Academy of Molecular Imaging. Gaylord, FL, US.
2006. Evaluation of Recurrences by PET/CT. Invited. IASLC - Workshop o Stereotactic Radiation Therapy and Surgery for Stage 1 Non-Small Cell Lung Cancer. Maui, HI, US.
2006. Monitoring Treatment Response with PET: Current Clinical Issues. Invited. Society of Nuclear Medicine Midwinter Educational Symposium. Tempe, AZ, US.
2006. PET/CT for Early Response and Prognosis in Lung Cancer. Invited. 6th Annual Targeted Therapies in the Treatment of Lung Cancer Conference. Santa Monica, CA, US.
2006. PET/CT in Thoracic Tumors. Invited. Colorado Radiological Society. Denver, CO, US.
2006. PET/CT in GYN Tumors. Invited. Colorado Radiological Society. Denver, CO, US.
2005. PET & Hybrid Imaging in the Evaluation of Lung Cancer. Invited. Radiological Society of North America. Chicago, IL, US.
2005. Keynote Speaker: Staging cancer with hybrid imaging. Invited. Radiological Society of North America. Chicago, IL, US.
2005. Lymphoma Imaging. Invited. Society of Nuclear Medicine Annual Meeting. Los Angeles, CA, US.
2004. Optimizing PET Imaging. Invited. Society of Nuclear Medicine Annual Meeting. Los Angeles, CA, US.
2003. PET in Esophageal Cancer. Invited. Academy of Molecular Imaging Annual Meeting. San Diego, CA, US.
2003. PET in Lung Cancer. Invited. National Diagnostic Imaging Symposium. Miami, FL, US.
2003. PET in Thyroid Cancer. Invited. Society of Nuclear Medicine Annual Meeting. Los Angeles, CA, US.
2003. PET in RT planning. Invited. Society of Nuclear Medicine Midwinter Educational Symposium. Hollywood, FL, US.
2002. PET in Lymphoma. Invited. Academy of Molecular Imaging Annual Meeting. San Diego, CA, US.
2002. PET in Lymphoma. Invited. American College of Radiology Annual Meeting. Miami, FL, US.
2002. Read with the Experts: PET (3 occurrences). Invited. Society of Nuclear Medicine Annual Meeting. Los Angeles, CA, US.

International Presentations

2023. Pain Management of Metastatic Skeletal Disease with Radiopharmaceuticals. Invited. International Atomic Energy Agency. Houston, US.
2023. General Introductory Discussion. Invited. International Atomic Energy Agency. Houston, US.
2023. Overview of Theranostics. Invited. International Atomic Energy Agency. Houston, US.
2023. Ajit Pandhy Oration. Invited. The World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). Accra, GH.
2023. PET/CT in Brain Tumors: Which Radiotracers Are Better?. Invited. XVI Symposium in PET/CT and SPECT/CT. Campinas, BR.
2023. PET/CT Image Acquisition Strategies to Improve Detection of Occult Primary Tumor. Invited. XVI Symposium in PET/CT and SPECT/CT. Campinas, BR.
2023. FDG PET/CT UPDATES: Primary Staging and Prognostic Value. Invited. XVI Symposium in PET/CT and SPECT/CT. Campinas, BR.
2020. Role of PET/CT in Colon Cancer. Invited. International Conference on Molecular Imaging and Clinical PET-CT in the Era of Theranostics (IPET-2020). Virtual, AT.
2019. Defining Thresholds for Quantitative SPECT/CT Imaging: Experiences to date, what we need clinically, and next steps. Invited. Siemens Healthlines. Lausanne, CH.
2019. PET/CT Pitfalls: Clinical Importance to the Radiologist and Oncologist. Invited. Mountain Area Health Education Center. Havana, CU.
2019. PET/CT: What you need to know as an effective 'Oncologic Radiologist'. Invited. Mountain Area Health Education Center. Havana, CU.
2018. Overview of Clinical applications of SPECT/CT and PET/CT in Oncology. Invited. International Atomic Energy Agency. Ulaanbaatar, MN.
2018. Oncology Session: Detection of Skeletal Metastases with hybrid imaging. Invited. International Atomic Energy Agency. Ulaanbaatar, MN.
2018. Oncology Session: The evolving role of Nuclear Medicine in the multidisciplinary care of oncology patients. Invited. International Atomic Energy Agency. Ulaanbaataar, MN.
2018. Oncology Session: Treatment of Skeletal Metastasis with alpha and beta emitters. Invited. International Atomic Energy Agency. Ulaanbaatar, MN.
2018. Session 6 Systemic therapy of Prostate Cancer: New and Future Therapeutic Radionuclides - 223Ra theray (Xofigo). Invited. WFNMB Post World Congress Symposium. Cairns, AU.
2018. Therapy Response Assessment with FDG-18F PET/CT in Solid Tumors: Timing and Interpretation. Invited. XIII Professor Edwaldo Camargo Symposium. Fortaleza, BR.
2018. Theranostics: State of the Art and Future Perspectives. Invited. XIII Professor Edwaldo Camargo Symposium. Fortaleza, BR.
2018. Update - PET/CT in Restaging and Evaluation of Therapy Response. Invited. XIII Professor Edwaldo Camargo Symposium. Campinas, BR.
2018. The Impact of PET/CT in Mesothelioma. Invited. XIII Professor Edwaldo Camargo Symposium. Campinas, BR.
2018. Impact of PET/CT n Radiotherapy. Invited. XIII Professor Edwaldo Camargo Symposium. Campinas, BR.
2018. Current Trends of PET/CT in Primary Staging in NSCLC. Invited. XIII Professor Edwaldo Camargo Symposium. Campinas, BR.
2018. Evaluation of response to immunotherapy with special focus on lymphoma with FDG PET/CT. Conference. International Atomic Energy Agency. Houston, US.
2017. Palliation and Improving the Survival of Patients with Skeletal Metastases (Sr-89/Sm153/Ra-223). Conference. American University of Beirut Medical Center. Beirut, LB.
2017. Future Directions of Theranostics in the Multidisciplinary Care of Cancer Patients (MD Anderson Perspective). Invited. American University of Beirut Medical Center. Beirut, LB.
2017. Lu177 Quant & Dosi & DRT. Invited. EANM 2017 Congress. Vienna, AT.
2017. Looking Beyond the Visible; New Frontiers in Diagnostic Techniques - Atoms for imaging: Latest trends in medical imaging from macro to micro. Conference. IAEA General Conference. Vienna, AT.
2017. Oncologic Evaluation by Nuclear Medicine and Clinical Application for Therapeutic Stragegy. Conference. 76th Annual Japan Radiological Society. Yokohama, JP.
2017. Professional Learning and the Development of Competencies in Nuclear Medicine. Conference. IAEA Technical Meeting. Vienna, AT.
2016. Functional imaging - the MD Anderson Cancer Center experience. Invited. 2016 AANMS Masterclass. Pilanesberg, ZA.
2016. Nuclear Medicine in the treatment of Prostate Cancer - Lu177 PSMA, XOFIGO. Invited. 2016 AANMS Masterclass. Pilanesberg, ZA.
2016. Nuclear Medicine in the imaging of Prostate Cancer - Ga68 PSMA and other tracers. Invited. 2016 AANMS Masterclass. Pilanesberg, ZA.
2016. Clinical Utilization of Ra-223 therapy at MD Anderson Cancer Center. Invited. SASNM 17th Biennial Congress. CSIR, ZA.
2016. Evolving role of Nuclear Medicine in Multi-Disciplinary Care of oncology patients. Invited. IAEA Regional Training Course. Seoul.
2016. Hybrid imaging (SPET/CT), PET/CT) and treatment of radioiodine refractory thyroid cancer. Invited. IAEA Regional Training Course. Seoul.
2016. Hybrid imaging for the staging of patients with breast cancer. Invited. IAEA Regional Training Course. Seoul.
2016. Ra-223 dichloride therapy for improving survival in patients with metastatic castrate resistant prostate cancer. Invited. IAEA Regional Training Course. Seoul.
2016. Hybrid imaging for the management of patients with upper gastrointestinal tract malignancies. Invited. IAEA Regional Training Course. Seoul.
2016. Utility of beta therapies for palliation of skeletal metastases. Invited. IAEA Regional Training Course. Seoul.
2016. Detection of skeletal metastases with hybrid imaging. Invited. IAEA Regional Training Course. Seoul.
2016. Radiommunotherapy of Lymphoma. Invited. IAEA Regional Training Course. Seoul.
2016. Role of FDG PET/CT and Diagnostic CT in the management of lymphoma. Invited. IAEA Regional Training Course. Seoul.
2016. PET/CT in Lung Cancer. Invited. International Symposium of Nuclear Medicine. Novi Sad.
2016. Read with the Expert: PET/CT in Lung Cancer. Invited. International Symposium of Nuclear Medicine. Novi Sad.
2016. Role of PET/CT in Evaluating Response to Targeted Therapy. Invited. 2016 PSNM Convention. Manila, PH.
2016. Evolving Role of Nuclear Medicine in Multidisciplinary Cancer Care. Invited. 2016 PSNM Convention. Manila, PH.
2016. Clinical Practice Guidelines in mCRPC - Nuclear Medicine Perspective. Invited. American Society of Clinical Oncology. San Francisco, US.
2015. Alpha Therapy. Invited. IAEA Training Course. Bangkok, TH.
2015. PERCIST and Metabolic Response Monitoring. Invited. IAEA Training Course. Bangkok, TH.
2015. PET/CT contrast usage; why and when. Invited. IAEA Training Course. Bangkok, TH.
2015. Read with the Expert: Lung cancer: staging and restaging. Invited. IAEA Training Course. Bangkok, TH.
2015. SPECT/CT in oncology and clinical applications. Invited. IAEA Training Course. Bangkok, TH.
2015. Read with the Expert: Head and Neck. Invited. IAEA Training Course. Bangkok, TH.
2015. Evolving Role of Nuclear Medicine in the Multi-Disciplinary Treatment of Cancer. Invited. 29th Brazilian Congress of Nuclear Medicine. Rio de Janeiro, BR.
2015. The role of PET/CT in The evaluation of response to targeted therapy. Invited. 29th Brazilian Congress of Nuclear Medicine. Rio de Janeiro, BR.
2015. Brave new world of management inpatients with prostate cancer advanced - The contribution of Nuclear Medicine in this new scenario. Invited. 29thBrzilian Congress of Nuclear Medicine. Rio de Janiero, BR.
2015. Read with the Expert, PET/CT: Lung Cancer. Invited. International Conference on Clinical PET-CT and Molecular Imaging (IPET 2015). Vienna, AT.
2015. PET/CT Imaging in Lung Cancer. Invited. International Conference on Clinical PET-CT and Molecular Imaging (IPET 2015). Vienna, AT.
2015. The Importance of PET/CT in Human Health. Invited. International Conference on Clinical PET-CT and Molecular Imaging (IPET 2015). Vienna, AT.
2015. Chair - Plenary Session II: Hybrid Iaging and Other Imaging Techniques in Breast Cancer. Invited. International Coferene on Clinical PET-CT and Molecular Imaging (IPET 2015). Vienna, AT.
2015. Current and Future Directions of Beta Therapies. Invited. 2nd HIAE International Congress of Diagnostic Imaging. Sao Paulo, ES.
2015. Current and Future Directions of Alpha Therapies. Invited. 2nd HIAE International Congress of Diagnostic Imaging. Sao Paula, ES.
2015. Evolving Role of Molecular Imaging in Multi-Disciplinary Cancer Care. Invited. 2nd HIAE International Congress of Diagnostic Imaging. Sao Paulo, ES.
2015. Breast Cancer Staging - Role of CT. Invited. Centre for Diagnostic Nuclear Imaging Universiti Putra Malaysia. Kuching, Sarawak, MY.
2015. Cancer Staging Using TNM system: an overview. Invited. Centre for Diagnostic Nuclear Imaging Universiti Putra Malaysia. Kuching, Sarawak, MY.
2015. Important TNM Updates. Invited. Centre for Diagnostic Nuclear Imaging Universiti Putra Malaysia. Kuching, Sarawak, MY.
2015. Nuclear Medicine in Cancer Staging. Invited. Centre for Diagnostic Nuclear Imaging Universiti Putra Malaysia. Kuching, Sarawak, MY.
2015. PET-CT in Cross Sectional Oncology Staging (Case Mix Presentation). Invited. Centre for Diagnostic Nuclear Imaging Universiti Purtra Malaysia. Kuching, Sarawak, MY.
2015. Cross Sectional Imaging in Staging Upper GIT Malignancy. Invited. Centre for Diagnostic Nuclear Imaging Universiti Putra Malaysia. Kuching, Sarawak, MY.
2015. Cross Sectional Imaging in Staging Lymphoma. Invited. Centre for Diagnostic Nuclear Imaging Universiti Putra Malaysia. Kuala Lumpur, MY.
2015. Current practices in Hybrid Imaging PETCTMR in US and training program. Invited. Centre for Diagnostic Nuclear Imaging Universiti Putra Malaysia. Kuala Lumpur, MY.
2015. Current and Future Trends for the Utilization of PET for Treatmment Strategy. Invited. Japanese Society of Medical Oncology. Sapporo, JP.
2015. Role of Nuclear Medicine Physician in the treatment of Advanced Prostate Cancer. Invited. Bayer. Monterry, MX.
2015. Evolution of clinical PET practice and future of the modality with new technology developments. Invited. Meet the Experts. Toulouse, FR.
2015. The Role of Nuclear Medicine Physician in the Current Scenario of Treatment of Advanced Prostate Cancer. Invited. Bayer. Sao Paulo, BR.
2014. Expert Mission - November 17 - 21, 2014. Invited. Philippine Nuclear Research Institute. Manila, PH.
2014. Nuclear Medicine & Bone Metastases. Invited. 32nd National Oncology Congress. Cancun, MX.
2014. Changes in Clinical Practice Driven by Imaging Trends, Oncology. Invited. Technical Meeting on Future of Nuclear Medicine & Diagnostic Imaging. Vienna, AT.
2014. PET/CT in Respiratory Infections and Inflammations. Invited. IX Symposium of PET/CT in Oncology & VI Symposium of SPECT/CT in Oncology. Sao Paulo, BR.
2014. PET/MR & Other Prospects for PET/CT in Lung Cancer of Non-Small Cell. Invited. Institute of Sirio-Libanese. Sao Paulo, BR.
2014. Role of PET/CT in Primary Staging. Invited. Institute of Sirio-Libanese. Sao Paulo, BR.
2014. PET/CT in Restaging & Statement Response. Invited. Institute of Sirio-Libanes. Sao Paulo, BR.
2014. ABC's of Therapy: Alpha, Beta or Immuno?. Invited. International Institute Continuing Medical Education (IICME). Cabo San Lucas, MX.
2014. Parathyroid Adenoma 4D/CT & SPECT/CT. Invited. International Institute Continuing Medical Education (IICME). Cabo San Lucas, MX.
2014. PET/CT & SPECT Acular CT for Oncologic Diagnosis & Staging. Invited. International Institute Continuing Medical Education (IICME). Cabo San Lucas, MX.
2014. What One Should Know to be an Effective Member of a Multi-disciplinary Team. Invited. International Institute Continuing Medical Education (IICME). Cabo San Lucas, MX.
2014. Kidney, Bladder, Urinary Tract & Penile Cancer. Conference. International Institute Continuing Medical Education (IICME). Cabo San Lucas, MX.
2013. PET/CT Imaging Best Practices at MD Anderson Cancer Center. Invited. St. Luke's Medical Center. Manila, PH.
2013. Alpha therapy and PET/SPECT imaging of metastatic bone disease. Invited. World Association of Radiopharmaceutical & Molecular Therapy. Manila, PH.
2013. Non-Oncology PET, Instrumentation. Invited. International Atomic Energy Agency (IAEA). Mumbai, IN.
2013. Novel Tracers. Invited. International Atomic Energy Agency (IAEA). Mumbai, IN.
2013. PET/CT in RTP. Invited. International Atomic Energy Agency (IAEA). Mumbai, IN.
2013. SPECTacular SPECT/CT. Invited. International Atomic Energy Agency (IAEA). Mumbai, IN.
2013. PET/CT Best Practices. Invited. International Atomic Energy Agency (IAEA). Mumbai, IN.
2013. PET/CT for Assessment of Response to Therapy. Invited. International Atomic Energy Agency. Doha, QA.
2013. PET/CT in Head and Neck Cancer. Invited. International Atomic Energy Agency. Doha, QA.
2013. PET/CT in Lung Nodule Evaluation, Lung Cancer, & Esophageal Cancer. Invited. International Atomic Energy Agency. Doha, QA.
2013. Introduction to Hybrid Image Technology and Image Fusion. Invited. International Atomic Energy Agency. Doha, QA.
2013. Best Practices For PET/CT in Oncology: Planning, Imaging, Reporting. Invited. International Atomic Energy Agency. Chiang Mai, TH.
2012. SCLC and Thyroid Cancer. Invited. World Class CME. Lake Buena Vista, US.
2012. Bone Metastases: F-18 NaF or FDG. Invited. World Class CME. Lake Buena Vista, US.
2012. Imaging Protocols and Reporting PET/CT. Invited. World Class CME. Lake Buena Vista, US.
2012. Treatment Planning - Oropharynx: PET/CT in Treatment Planning. Invited. International Atomic Energy Agency. Brescia, IT.
2012. Post-Treatment Assessment - Oropharynx: PET/CT Findings. Invited. International Atomic Energy Agency. Brescia, IT.
2012. Larynx & Hypopharnyx: PET/CT in Treatment Planning. Invited. International Atomic Energy Agency. Brescia, IT.
2012. Clinical PET/CT: Operations, Quality Assurance and Reporting. Invited. International Atomic Energy Agency. Brescia, IT.
2012. Strategic Utilization of PET Imaging for Cancer Therapy. Invited. 52nd Annual Scientific Meeting of the Japanese Society of Nuclear Medicine. Sapporo, JP.
2012. Molecular Imaging Progress in Clinical Oncology. Invited. International Institute Continuing Medical Education (IICME). Williamsburg, US.
2012. Abdominal Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Williamsburg, US.
2012. Pelvic Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Williamsburg, US.
2012. Chest Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Williamsburg, US.
2012. Clinical Implications of Quality Management in Hybrid Modalities. Invited. International Atomic Energy Agency (IAEA). Vienna, AT.
2012. PET/CT in Oncology. Invited. International Atomic Energy Agency (IAEA). Vienna, AT.
2012. Future Directions of PET/CT and PET/MR. Invited. Iberoamerican Congress on Interventional Radiology, and National Congress of Radiology. Panama City, PA.
2012. Clinical Utility of FDG PET/CT in Staging and Restaging of Cancer. Invited. Iberoamerican Congress on Interventional Radiology, and National Congress of Radiology. Panama City, PA.
2012. Monitoring Response with FDG PET/CT. Invited. Iberoamerican Congress on Interventional Radiology, and National Congress of Radiology. Panama City, PA.
2012. Nuts and Bolts of Assessing Response by PET/CT: "Is it the same, better or worse?". Invited. American Society of Clinical Oncology (ASCO). Chicago, US.
2012. FDG PET/CT in Head and Neck Cancer. Invited. International Congress of PET/CT. Cali, CO.
2012. FCG PET/CT in Lymphoma. Invited. International Congress of PET/CT. Cali, CO.
2012. SUV: Monitoring Response in Clinical Practice. Invited. International Congress of PET/CT. Cali, CO.
2012. FDG PET/CT in Breast Cancer. Invited. International Congress of PET/CT. Cali, CO.
2012. PET/CT in Thyroid Cancer. Invited. International Congress of PET/CT. Cali, CO.
2012. PET/CT for Therapy Planning, Response Evaluation & Future Directions. Invited. ANZSNM. Queenstown, NZ.
2012. Cancer Imaging; Staging and Therapy Monitoring with PET/CT. Invited. ISMRM 20th Annual Meeting. Melbourne, AU.
2012. SPECT/CT and PET/CT Imaging of Skeletal Metastases. Invited. 27th ICR 2012 and 42nd JPR 2012. Sao Paulo, BR.
2012. Molecular Imaging in the Era of Molecular Therapy. Invited. 27th ICR 2012 and 42nd JPR 2012. Sao Paulo, BR.
2012. FCT PET/CT in Lung Cancer Screening, NSCLS and SCLC. Invited. 27th ICR 2012 and 42nd JPR 2012. Sao Paulo, BR.
2012. Cost Effectiveness of FDG PET/CT. Invited. 27th ICR 2012 and 42nd JPR 2012. Sao Paulo, BR.
2012. Future Directions for PET/CT and SPECT/CT. Invited. 7th PET/CT in Oncology Symposium & IV SPECT/CT in Oncology Symposium. Sao Paulo, BR.
2012. Use of FDG PET/CT in the NCCN Clinical Practice Guidelines in Oncology (Lung Cancer). Invited. Philippine Society of Nuclear Medicine. Manila, PH.
2012. Clinical Radionuclide Imaging of Musculoskeletal Malignancies (SPECT/CT, PET/CT, PET/MR). Invited. Philippine Society of Nuclear Medicine. Manila, PH.
2011. Clinical Applications of Non-FDG PET Tracers. Invited. 14th World Conference on Lung Cancer. Vienna, AT.
2011. ARCCNM - Panel Discussion: Issues on Sustainability of Clinical PET in Asia. Invited. 14th World Conference on Lung Cancer. Vienna, AT.
2011. Cost Effectiveness of PET/CT with a Focus on Developing Third World. Invited. 14th World Conference on Lung Cancer. Vienna, AT.
2011. Read with the Expert: PET/CT Head and Neck. Invited. 14th World Conference on Lung Cancer. Vienna, AT.
2011. Pelvic Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Half Moon Bay, US.
2011. SPECT/CT: The MD Anderson Experience. Invited. International Institute Continuing Medical Education (IICME). Half Moon Bay, US.
2011. Case-based Reviews: Lung, Breast, Abdomen, Pelvis. Invited. International Institute Continuing Medical Education (IICME). Half Moon Bay, US.
2011. Abdominal Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Half Moon Bay, US.
2011. Chest Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Half Moon Bay, US.
2011. Molecular Imaging in Clinical Oncology: Imaging Guided Personalized Therapy. Invited. International Institute Continuing Medical Education (IICME). Half Moon Bay, US.
2011. SPECT/CT: The MD Anderson Experience. Invited. International Institute Continuing Medical Education (IICME). Hilton Head, US.
2011. Abdominal Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Hilton Head, US.
2011. Pelvic Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Hilton Head, US.
2011. Chest Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Hilton Head, US.
2011. PET/CT in Guiding Minimally Invasive Staging. Invited. University of Otago. Wellington, NZ.
2011. SPECT/CT in Lymphoscintigraphy. Invited. University of Otago. Wellington, NZ.
2011. Consistency is Key. Invited. University of Otago. Wellington, NZ.
2011. Role of SPECT/CT in Therapy. Invited. University of Otago. Wellington, NZ.
2011. PET and Radiotherapy: Proliferation, Hypoxia, Angiogenesis. Invited. ANZSNM 41st Annual Scientific Meeting. Darwin, AU.
2011. PET FDG and Antibody - Free Papers. Invited. ANZSNM 41st Annual Scientific Meeting. Darwin, AU.
2011. Pearls and Pitfalls - Interactive Case Session. Invited. ANZSNM 41st Annual Scientific Meeting. Darwin, AU.
2011. Role of SPECT/CT in Therapy. Invited. ANZSNM 41st Annual Scientific Meeting. Darwin, AU.
2011. PET: Guiding Minimally Invasive Staging. Invited. ANZSNM 41st Annual Scientific Meeting. Darwin, AU.
2011. SPECT/CT in Lymphoscintigraphy. Invited. ANZSNM 41st Annual Scientific Meeting. Darwin, AU.
2011. Molecular Imaging in the Era of Molecular Therapy. Invited. ANZSNM 41st Annual Scientific Meeting. Darwin, AU.
2011. Consistency is Key. Invited. Concord Hospital. Sydney, AU.
2011. Chair: Oral Session "New Image Guided Approaches for Tumor Characterization & Prediction of Therapy Outcome in NSCLC". Invited. 14th Annual World Conference on Lung Cancer. Amsterdam, NL.
2011. New IASLC Staging System: Implications for CT-Reading. Invited. 14th Annual World Conference on Lung Cancer. Amsterdam, NL.
2011. PET/CT in the Staging of Hodgkin's and Non-Hodgkin's Lymphoma. Invited. VI PET/CT Symposium in Oncology. Sao Paulo, BR.
2011. PET/CT in the Re-Staging of Lymphoma. Invited. VI PET/CT Symposium in Oncology. Sao Paulo, BR.
2011. PET/CT in Response to Therapy of Lymphoma. Invited. VI PET/CT Symposium in Oncology. Sao Paulo, BR.
2011. Technical Aspects of the Use of PET/CT in Children. Invited. VI PET/CT Symposium in Oncology. Sao Paulo, BR.
2011. PET/CT in Melanoma. Invited. VI PET/CT Symposium in Oncology. Sao Paulo, BR.
2011. SPECT/CT Lymphoscintigraphy in Melanoma of the Head and Neck: The MDACC Experience. Invited. III SPECT/CT Symposium in Oncology. Sao Paulo, BR.
2011. PET/CT in Sarcomas. Invited. VI PET/CT Symposium in Oncology. Sao Paulo, BR.
2011. PET/CT and SPECT/CT Pediatric Brain Tumors. Invited. III SPECT/CT Symposium in Oncology. Sao Paulo, BR.
2011. PET/CT in Germ Cell Tumors. Invited. VI PET/CT Symposium in Oncology. Sao Paulo, BR.
2011. PET/CT in Hepatoblastoma, Neurofibromatosis, Histiocytosis. Invited. VI PET/CT Symposium in Oncology. Sao Paulo, BR.
2011. PET/CT and SPECT/CT in Neuroblastoma. Invited. III SPECT/CT Symposium in Oncology. Sao Paulo, BR.
2010. PET/CT & SPECTacular CT in Head & Neck Tumors. Invited. International Atomic Energy Agency. Pucon, CL.
2010. Clinical Utility of FDG PET/CT in Breast Cancer. Invited. International Atomic Energy Agency. Pucon, CL.
2010. Utilization of PDG PET/CT in Colorectal Cancer. Invited. International Atomic Energy Agency. Pucon, CL.
2010. Chest Tumors with FDG PET/CT. Invited. Society of Nuclear Medicine Indian Congress 2010. Chandigarh, IN.
2010. SPECTacular/CT in Head & Neck Tumors. Invited. Society of Nuclear Medicine Indian Congress 2010. Chandigarh, IN.
2010. FDG PET/CT in Oncology: Special Cases. Invited. European Association of Nuclear Medicine. Vienna, AT.
2010. Do We Need Guidelines in Reporting?. Invited. European Association of Nuclear Medicine. Vienna, AT.
2010. Monitoring Treatment Response with PET/CT in Clinical Practice. Invited. Society of Nuclear Medicine Puerto Rico. San Juan, PR.
2010. Elements of PET/CT Reporting: SNM PET Center of Excellence. Invited. Society of Nuclear Medicine Puerto Rico. San Juan, PR.
2010. Emerging Technologies - Challenges and Opportunities. Invited. International Atomic Energy Agency. Vienna, AT.
2010. Meet the Doctors: A Simulated Tumor Board. Invited. International Atomic Energy Agency. Vienna, AT.
2010. Abdominal Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Sonoma, US.
2010. Pelvic Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Sonoma, US.
2010. Chest Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education (IICME). Sonoma, US.
2010. SPECT/CT: The MD Anderson Experience. Invited. International Institute Continuing Medical Education (IICME). Sonoma, US.
2010. PET/CT in Pediatric Malignancies. Invited. International Atomic Energy Agency. Bombay, IN.
2010. PET/CT in RT Planning. Invited. International Atomic Energy Agency. Bombay, IN.
2010. Ideal PET/CT Report. Invited. International Atomic Energy Agency. Bombay, IN.
2010. FDG PET in Thoracic Malignancies. Invited. International Atomic Energy Agency. Bombay, IN.
2010. PET/CT Good Practices in Oncology. Invited. International Atomic Energy Agency. Bombay, IN.
2010. Future directions of PET/CT imaging in oncology. Invited. 40th Sao Paul Radiology Meeting (JPR '2010) and 1st Brazil-Italy Congress of Radiology. Sao Paulo, BR.
2010. Current challenges for PET/CT in pelvic tumors. Invited. 40th Sao Paul Radiology Meeting (JPR '2010) and 1st Brazil-Italy Congress of Radiology. Sao Paulo, BR.
2010. Current challenges for PET/CT imaging of chest tumors. Invited. 40th Sao Paul Radiology Meeting (JPR '2010) and 1st Brazil-Italy Congress of Radiology. Sao Paulo, BR.
2010. Monitoring treatment response with PET/CT in clinical practice. Invited. 40th Sao Paul Radiology Meeting (JPR '2010) and 1st Brazil-Italy Congress of Radiology. Sao Paulo, BR.
2010. Reporting guidelines for FDG PET/CT - SNM PET Center of Excellence. Invited. 40th Sao Paul Radiology Meeting (JPR '2010) and 1st Brazil-Italy Congress of Radiology. Sao Paulo, BR.
2010. Guidelines in PET/CT and SPECT/CT. Invited. 5th Annual PET/CT Symposium in Oncology. Sao Paulo, BR.
2010. The role of PET/CT and SPECT/CT in the evaluation of viability of central nervous system tumors. Invited. 5th Annual PET/CT Symposium in Oncology. Sao Paulo, BR.
2010. The role of PET/CT in the detection of occult tumors. Invited. 5th Annual PET/CT Symposium in Oncology. Sao Paulo, BR.
2010. The role of PET/CT in the restaging and treatment response of head and neck tumors. Invited. 5th Annual PET/CT Symposium in Oncology. Sao Paulo, BR.
2009. PET in Oral Cancer. Invited. Chang Gung Memorial Hospital Cancer Symposium. Taipei, TW.
2009. PET in NSCLS: Today and Tomorrow. Invited. Society of Nuclear Medicine Annual Meeting. Taipei, TW.
2009. PET in NSCLC: Today and Tomorrow. Invited. Chang Gung Memorial Hospital Cancer Symposium. Taipei, TW.
2009. Abdominal tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education. Sonoma, US.
2009. Chest Tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education. Sonoma, US.
2009. SPECT/CT for parathyroid adenomas. Invited. International Institute Continuing Medical Education. Sonoma, US.
2009. Pelvic tumors with FDG PET/CT. Invited. International Institute Continuing Medical Education. Sonoma, US.
2009. PET for radiation treatment planning. Invited. International Atomic Energy Agency. Beijing, CN.
2009. PET/CT in melanoma. Invited. International Atomic Energy Agency. Beijing, CN.
2009. PET/CT in Ovarian and uterine CA. Invited. International Atomic Energy Agency. Beijing, CN.
2009. PET/CT in esophageal CA. Invited. International Atomic Energy Agency. Beijing, CN.
2009. When does PET add value to clinical oncology practice. Invited. International Atomic Energy Agency. Beijing, CN.
2009. PET/CT in lung CA. Invited. International Atomic Energy Agency. Beijing, CN.
2009. Imaging response and surveillance (PET/CT). Invited. 13th World Conference on Lung Cancer. San Francisco, US.
2009. New imaging tools for diagnosis and therapy monitoring in lung cancer. Invited. 13th World Conference on Lung Cancer. San Francisco, US.
2009. Staging of cancer with FDG PET/CT. Invited. International Atomic Energy Agency. Singapore, SG.
2008. Use of PET/CT in the diagnosis & staging of cancer. Invited. CANCER 2008. Cali, CO.
2008. Use of PET/CT in the evaluation of tumor response. Invited. CANCER 2008. Cali, CO.
2008. Diagnosis & prognosis in cancer of the esophagus. Invited. XXXVII Brazilian Congress of Radiology. Belo Horizonte, BR.
2008. Evaluation of response in lymphoma with PET/CT. Invited. XXXVII Brazilian Congress of Radiology. Belo Horizonte, BR.
2008. PET/CT in cancer of the head & neck and thyroid. Invited. XXXVII Brazilian Congress of Radiology. Belo Horizonte, BR.
2008. Radiotherapy planning with PET/CT. Invited. XXXVII Brazilian Congress of Radiology. Belo Horizonte, BR.
2008. Study and diagnosis of non-small cell lung cancer with PET/CT. Invited. XXXVII Brazilian Congress of Radiology. Belo Horizonte, BR.
2008. Scientific Session: Overcoming challenges in clinical translation of novel radiotracers. Invited. World Molecular Imaging Conference. Nice, FR.
2008. Panel Chair: Functional Imaging. Invited. Annual International Conference on Head & Neck. San Francisco, US.
2008. Utility of PET in Radiotherapy Planning. Invited. IAEA Regional Training Course on Fundamental Clinical Applications of PET. Singapore, SG.
2008. How to Report a PET/CT Study. Invited. IAEA Regional Training Course on Fundamental Clinical Applications of PET. Singapore, SG.
2008. Utility of FDG PET/CT in Esophageal Cancer. Invited. IAEA Regional Training Course on Fundamental Clinical Applications of PET. Singapore, SG.
2008. Scientific Session: Interesting PET/CT Cases. Invited. IAEA Regional Training Course on Fundamental Clinical Applications of PET. Singapore, SG.
2008. Staging of NSCLC with FDG PET/CT. Invited. IAEA Regional Training Course on Fundamental Clinical Applications of PET. Singapore, SG.
2008. Early Response Evaluation in Lymphoma with FDG. Invited. IAEA Regional Training Course on Fundamental Clinical Applications of PET. Singapore, SG.
2008. PET/CT Imaging with Tracers other than FDG. Invited. 38th Sao Paulo Radiology Meeting (JPR 2008). Sao Paulo, BR.
2008. Best Practice: Optimized CT and Structured Reporting for Oncologic FDG PET/CT. Invited. 38th Sao Paulo Radiology Meeting (JPR 2008). Sao Paulo, BR.
2008. Update on SPECT/CT Imaging in Oncology. Invited. 38th Sao Paulo Radiology Meeting (JPR 2008). Sao Paulo, BR.
2008. Keynote Speaker: PET/CT in Radiotherapy Planning - Data Acquisition and Transfer to Radiotherapy. Invited. Annual PET Symposium. Sao Paulo, BR.
2007. Therapy Assessment and Planning in Lung Cancer. Invited. International Conference on Clinical PET and Molecular Nuclear Medicine. Bangkok, TH.
2007. Oncology Melanoma. Invited. International Conference on Clinical PET and Molecular Nuclear Medicine. Bangkok, TH.
2007. PET/CT Colorectal Cancer: State of the Art. Invited. XI Colombian Nuclear Medicine Congress. Bogota, CO.
2007. PET/CT Lung Carcinoma: State of the Art. Invited. XI Colombian Nuclear Medicine Congress. Bogota, CO.
2007. SPECT-PET/CT. Invited. XI Colombian Nuclear Medicine Congress. Bogota, CO.
2007. Molecular Imaging for Efficacy Evaluation. Invited. 12th World Conference on Lung Cancer. Seoul.
2007. Keynote Speaker: Young Investigator's Award. Invited. 12th World Conference on Lung Cancer. Seoul.
2007. Keynote Speaker: PET/CT in the Assessment of Image Guided Therapy in Metastatic Colorectal Cancer. Invited. Annual PET Symposium. Sao Paulo, BR.
2007. Current Status of the Use of PET/CT in Colorectal Cancer. Invited. PET/CT in Oncology: GI Tract Cancer. Sao Paulo, BR.
2006. SPECT/CT: Clinical Applications and Perspectives. Invited. 2nd Uruguayan Congress of Nuclear Medicine. Montevideo, UY.
2006. PET/CT in Radiotherapy Planning. Invited. 2nd Uruguayan Congress of Nuclear Medicine. Montevideo, UY.
2006. Keynote Speaker: PET/CT in the Evaluation of Lung Cancer. Invited. 2nd Uruguayan Congress of Nuclear Medicine. Montevideo, UY.
2006. PET/CT: Diagnosis and Follow-up. Invited. Argentinean Congress of Biology and Nuclear Medicine. Buenos Aires, AR.
2006. Keynote Speaker: Treatment with Radioimmunocompounds. Invited. Argentinean Congress of Biology and Nuclear Medicine. Buenos Aires, AR.
2006. Monitoring Radiotherapy Using PET. Invited. World Congress of Nuclear Medicine and Biology. Seoul.
2006. PET in Esophageal Cancer. Invited. World Congress of Nuclear Medicine and Biology. Seoul.
2006. Iodine 124 PET Imaging and Thyroid Cancer. Invited. MDACC-Institute Gustave Rouissy Symposium. Paris, FR.
2006. PET and Early Response Assessment. Invited. MDACC-Institute Gustave Rouissy Symposium. Paris, FR.
2006. PET Imaging Techniques to Detect Early Disease. Invited. International Association for the Study of Lung Cancer (IASLC). Turino, IT.
2006. PET/CT Update and SPECT/CT. Invited. International Atomic Energy Agency. Manila, PH.
2006. Round Table Discussion: Optimal application of EGFR inhibitors. Invited. 7th International Lung Cancer Congress. Maui, US.
2006. PET/CT for Non-Invasive Mediastinal Staging of NSCLS. Invited. 7th International Lung Cancer Congress. Maui, US.
2006. Advanced Imaging Techniques for Early Response Evaluation. Invited. Hospital Sirio-Libanes. Sao Paulo, BR.
2006. PET/CT in Pediatrics. Invited. Hospital Sirio-Libanes. Sao Paulo, BR.
2006. PET/CT en neoplasias de pulmon, linfoma y colon. Invited. Hospital San Jose Tec de Monterrey. Monterrey, MX.
2006. PET/CT: Principles and practice. Invited. American Roentgen Ray Society 106th Annual Meeting. Vancouver, CA.
2006. PET. Invited. XXIII Annual Meeting. Puerto Vallarta, MX.
2005. PET/CT in NSCLC. Invited. World Conference Lung Cancer. Barcelona, ES.
2003. PET in IMRT. Invited. International IMRT Conference. Houston, US.
2002. Applications of PET in Oncology, Neurology, and Cardiology. Invited. International Atomic Energy Agency PET/Cyclotron Workshop. Manila, PH.

Formal Peers

2019. Interesting Cases for Trainees (Including Essential Elements of PET/CT Reporting). Invited. St. Louis, MO, US.
2019. Evolution of Nuclear Medicine in the Multidisciplinary Care of Cancer Patients at MD Anderson Cancer Centre. Visiting. St. Louis, MO, US.
2017. The Development of PET/CT and PET/MR clinical practices at MD Anderson Cancer Center. Visiting. Changsha, CN.
2016. Best practices in Clinical PET/CT at MD Anderson Cancer Center. Visiting. New York, NY, US.
2016. Evolving role of Nuclear Medicine in Multidisciplinary Cancer Care. Visiting. New York, NY, US.
2015. The Evolving Role of Clinical Molecular Imaging in Multi-Disciplinary Cancer Care. Invited. New York, NY, US.
2014. The Evolving Role of Clinical Molecular Imaging in Multi-Disciplinary Cancer Care. Visiting. Cleveland, OH, US.
2014. MD Anderson Cancer Center Clinical PET Program: Past, Present and Future Directions. Visiting. Palo Alto, CA, US.
2013. Current Status and Future Directions of PET/CT imaging in Oncology. Visiting. Orlando, FL, US.
2013. Imaging, Reporting PET/CT and Cases for Discussion. Visiting. Orlando, FL, US.
2012. The Value of FDG PET/CT in Oncology: Good, Better, and Best Practice. Visiting. Newark, DE, US.
2012. Update on PET/CT in Lung Cancer. Visiting. Baltimore, MD, US.
2012. PET/CT for Treatment Planning and Response Monitoring. Visiting. Hong Kong, CN.
2011. PET/CT: Role in Breast Cancer and Potential for Research. Visiting. Philadelphia, PA, US.
2010. FDG PET/CT in Head and Neck Cancer. Visiting. Philadelphia, PA, US.
2010. Imaging "The Prodigal Tumors". Invited. Las Vegas, NV, US.
2010. Evaluating Pelvic Tumors. Invited. Las Vegas, NV, US.
2010. PET/CT for Infection - Blessing or a Curse. Invited. Las Vegas, NV, US.
2010. Pick your Poison with Bone Metastases: MDP or FDG. Invited. Las Vegas, NV, US.
2010. PET Imaging in Neuro Disorders. Invited. New Orleans, LA, US.
2009. Added value of FDG PET/CT in oncology. Visiting. Buenos Aires, AR.
2009. Added value of FDG PET/CT in Oncology. Visiting. Buenos Aires, AR.
2009. FDG PET/CT in Colorectal Cancer. Visiting. Buenos Aires, AR.
2009. FDG PET/CT in Staging of Lung Cancer. Visiting. Buenos Aires, AR.
2009. FDG PET/CT in Head and Neck Cancer and Thyroid Cancer. Visiting. Buenos Aires, AR.
2009. Introduction to PET/CT. Visiting. Buenos Aires, AR.
2009. Clinical Utility of FCG PET/CR in General Practice. Invited. Grand Junction, CO, US.
2009. Nuts & Bolts of Oncologic FDG PET/CT Imaging. Invited. Milwaukee, WI, US.
2009. FDG PET/CT in Oncology - Impact on Patient Management. Invited. Milwaukee, WI, US.
2009. Utility of FDG PET/CT in Oncology & Neurology. Invited. Jackson, MS, US.
2009. PET/CT in Oncology: Impact on Patient Management. Invited. Omaha, NE, US.
2009. PET/CT in Breast Cancer. Visiting. Dallas, TX, US.
2008. The Current Status and Future Synergies of Molecular Imaging and Therapy. Visiting. Quezon City, PH.
2008. PET/CT - New Insights in Oncologic Imaging. Invited. San Antonio, TX, US.
2008. Lymphoscintigraphy: SPECTacular/CT. Visiting. Hershey, PA, US.
2008. Case Conference with Residents. Visiting. Hershey, PA, US.
2008. PET/CT in Oncology: Impact on Patient Management. Invited. Louisville, KY, US.
2008. Positron Emission Tomography Clinical Applications. Visiting. Wichita Falls, TX, US.
2008. PET/CT in Metastatic Breast Cancer. Visiting. New York, NY, US.
2008. PET/Ct in Colorectal Cancer. Visiting. Philadelphia, PA, US.
2007. PET/CT Cases. Visiting. Lansing, MI, US.
2007. PET/CT: Nuts & Bolts. Visiting. Lansing, MI, US.
2007. PET/CT Utilization in NSCLC and Esophageal Cancer. Visiting. Lansing, MI, US.
2007. PET Imaging. Visiting. Waukesha, WI, US.
2007. PET CT: IN GI & GU. Visiting. Boston, MA, US.
2007. PET CT: In GI & GU. Visiting. Boston, MA, US.
2006. PET/CT imaging in oncology. Visiting. London, GB.
2006. PET/CT in Male and Female Pelvic Malignancies. Visiting. Cambridge, MA, US.
2005. PET/CT in Oncology. Invited. Brussels, BE.

Less

Grant & Contract Support

Date:	2014 - 2016
Title:	Tumor mutation status will predict metabolic response to metformin in NSCLC
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R21CA182964-01A1

Date:	2014 - 2016
Title:	Image-guided Selection of High-risk Patients for Radiation Pneumonitis Prevention
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2014 - 2019
Title:	Southwest Early Clinical Trials Consortium
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1UM1CA186688-01

Date:	2012 - 2015
Title:	Multi-Modal Reconstruction and Quantitative SPECT Imaging
Funding Source:	Siemens
Role:	PI
ID:	LS2012-00036240LG 01

Date:	2011 - 2015
Title:	Evaluation of Interim FLT-PET/CT for Early Prediction of Outcome of Patients with Diffuse Large B-cell Lymphoma (DLBCL) Treated with R-CHOP
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01-CA 152923

Date:	2009 - 2014
Title:	18F-Fluoride PET/CT versus 99m Tc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging
Funding Source:	Academy of Molecular Imaging (AMI)
Role:	PI
ID:	CS2009-00027113LG

Date:	2009 - 2012
Title:	ARRA: A phase II study to test the correlation of a radiation pneumonitis imaging biomarker with clinical endpoints
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	CA 141833 01

Date:	2007 - 2011
Title:	A phase 2, open-label, proof-of-concept study to assess the ability to detect tumors and angiogenesis via the expression of alpha v beta 3 and 5 integrin receptors by (18F)AH-111585 PET imaging
Funding Source:	GE Healthcare
Role:	PI
ID:	CS2007-00020704RG

Date:	2007 - 2011
Title:	Phase II Validation of 4-Dimensional Computed Tomography Derived Ventilation for Image Guided Radiotherapy of Lung Cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	CA 128230 02

Date:	2006 - 2008
Title:	Early Prediction of Pathological Response of Chemotherapy with FLT PET
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01-CA89198-03

Date:	2005 - 2015
Title:	Program Project 2: Molecular Imaging of EGFR Expression and Activity in Targeted Therapy of Lung Cancer
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	W81XWH-05-20027M

Date:	2002 - 2007
Title:	Development of Poly-L-Glutamic Acid Paclitaxel Conjugate
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R42 CA80589-02A1

Selected Publications

Peer-Reviewed Articles

Brink A, Cerci JJ, Giammarile F, Yurystovskyi D, Korde A, Estrada-Lobato E, Mikhail-Lette M, Pellet O, Macapinlac HA, Paez D. Global Challenges in the Provision of Theranostic Services the International Atomic Energy Agency (IAEA) Perspective. World J Nucl Med 24(3):238-243, 2025. e-Pub 2025. PMID: 41221384.
Kairemo, K, Gouda, MA, Chuang, HH, Macapinlac, HA, Subbiah, V. Deciphering Tumor Response. Journal of Clinical Medicine 13(11), 2024. e-Pub 2024. PMID: 38892979.
Kairemo K, Gouda M, Chuang HH, Macapinlac HA, Subbiah V. Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors. J Clin Med 13(11):3269, 2024. e-Pub 2024. PMID: 38892979.
Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med 30(3):772-784, 2024. e-Pub 2024. PMID: 38238616.
Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
Kairemo K, Kangasmäki A, Kappadath SC, Joensuu T, Macapinlac HA. A Retrospective Comparative Study of Sodium Fluoride Na18F-PET/CT and 68Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis. Life (Basel) 12(12), 2022. e-Pub 2022. PMID: 36556342.
Jimenez JE, Dai D, Xu G, Zhao R, Li T, Pan T, Wang L, Lin Y, Wang Z, Jaffray D, Hazle JD, Macapinlac HA, Wu J, Lu Y. Lesion-based radiomics signature in pretherapy 18F-FDG PET predicts treatment response to Ibrutinib in lymphoma. Clin Nucl Med 47(3):209-218, 2022. e-Pub 2022. PMID: 35020640.
Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 63(1):74-83, 2022. e-Pub 2022. PMID: 34435552.
Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac HA, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol 27(47):8166-8181, 2021. e-Pub 2021. PMID: 35068861.
Kairemo K, Jessop AC, Vija AH, Ding X, Spence D, Kappadath SC, Macapinlac HA. A Prospective Comparative Study of Using Ultrasonography, 4D-CT and Parathyroid Dual-Phase Scintigraphy with SPECT in Patients with Primary Hyperparathyroidism. Diagnostics (Basel) 11(11):2006, 2021. e-Pub 2021. PMID: 34829354.
Lin M, Paolillo V, Le DB, Macapinlac HA, Ravizzini GC. Monoclonal antibody based radiopharmaceuticals for imaging and therapy. Curr Probl Cancer 45(5):100796, 2021. e-Pub 2021. PMID: 34657748.
Kairemo K, Roszik J, Anderson P, Ravizzini G, Rao A, Macapinlac HA, Subbiah V. 18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. Curr Probl Cancer 45(5):100797, 2021. e-Pub 2021. PMID: 34706830.
Minamimoto R, Fayad L, Vose J, Meza J, Advani R, Hankins J, Mottaghy F, Macapinlac H, Heinzel A, Juweid ME, Quon A. 18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study. Eur J Nucl Med Mol Imaging 48(9):2883-2893, 2021. e-Pub 2021. PMID: 33909086.
Baiomy A, Schellingerhout D, Chapin BF, Weinberg JS, Raza SM, Macapinlac HA, Ravizzini G. Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer. Nucl Med Commun 42(7):755-762, 2021. e-Pub 2021. PMID: 33741867.
Teyateeti A, Teyateeti A, Ravizzini GC, Xu G, Tang C, Tu SM, Macapinlac HA, Lu Y. Diagnostic performance of 18F-fluciclovine PET/CT in prostate cancer patients with rising PSA level = 0.5 ng/ml after multiple treatment failures. Am J Nucl Med Mol Imaging 11(2):87-98, 2021. e-Pub 2021. PMID: 34079638.
Zhou Z, Jain P, Lu Y, Macapinlac H, Wang ML, Son JB, Pagel MD, Xu G, Ma J. Computer-aided detection of mantle cell lymphoma on 18F-FDG PET/CT using a deep learning convolutional neural network. Am J Nucl Med Mol Imaging 11(4):260-270, 2021. e-Pub 2021. PMID: 34513279.
Kairemo K, Kappadath SC, Joensuu T, Macapinlac HA. A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using a Volumetric 3-D Radiomics Analysis. Diagnostics (Basel) 11(1), 2020. e-Pub 2020. PMID: 33374148.
Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac HA, Meric-Bernstam F, Hong DS, Pant S, Le D, Santos E, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G. Phase 1 Study of P-cadherin-Targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res 26(22):5830-5842, 2020. e-Pub 2020. PMID: 32816889.
Teyateeti A, Khan B, Chen B, Bridhikitti J, Pan T, Peng W, Macapinlac, HA, Lu Y. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level =0.5 ng/mL. Nucl Med Commun 41(9):906-915, 2020. e-Pub 2020. PMID: 32796479.
Teyateeti A, Macapinlac, HA, Lu Y. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?. Clin Nucl Med 45(9):672-678, 2020. e-Pub 2020. PMID: 32604105.
Lu Y, Macapinlac HA. Perfusion SPECT/CT to diagnose pulmonary embolism during COVID-19 pandemic. Eur J Nucl Med Mol Imaging 47(9):2064-2065, 2020. e-Pub 2020. PMID: 32383092.
Lu Y, Yan SX, Lan X, Zhu X, Macapinlac HA. Nuclear medicine in responding to global pandemic COVID-19-American College of Nuclear Medicine member experience. Eur J Nucl Med Mol Imaging 47(7):1620-1622, 2020. e-Pub 2020. PMID: 32296884.
Chen B, Bathala TK, Xu G, Teyateeti A, Chapin BF, Tang C, Tu SM, Macapinlac, HA, Lu Y. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Clin Nucl Med 45(5):349-355, 2020. e-Pub 2020. PMID: 31977495.
Kairemo K, Santos EB, Macapinlac HA, Patel S, Conley AP, Hong DS, Subbiah AV. Molecular Imaging with 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. Diagnostics (Basel) 10(3), 2020. e-Pub 2020. PMID: 32106426.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
Kairemo K, Santos EB, Macapinlac HA, Subbiah V. Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer. Diagnostics (Basel) 10(1), 2020. e-Pub 2020. PMID: 31935818.
Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 7:117-131, 2020. e-Pub 2020. PMID: 32984089.
Chen B, Wei P, Macapinlac, HA, Lu Y. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. Nucl Med Commun 40(9):940-946, 2019. e-Pub 2019. PMID: 31343613.
Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac, HA, Rohren E. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. Clin Cancer Res 25(13):3802-3810, 2019. e-Pub 2019. PMID: 30733229.
Vija AH, Bartenstein PA, Froelich JW, Kuwert T, Macapinlac H, Daignault CP, Gowda N, Hadjiev O, Hephzibah J, Huang P, Ilhan H, Jessop A, Cachovan M, Ma J, Ding X, Spence D, Platsch G, Szabo Z. ROC study and SUV threshold using quantitative multi-modal SPECT for bone imaging. Eur J Hybrid Imaging 3(1):10, 2019. e-Pub 2019. PMID: 34191147.
Dai D, Chuang HH, Macapinlac HA, Li T, Pan T. Correlation of fluorine 18-labeled sodium fluoride uptake and arterial calcification on whole-body PET/CT in cancer patients. Nucl Med Commun 40(6):604-610, 2019. e-Pub 2019. PMID: 30688757.
Chen B, Macapinlac HA, Lu Y. Superscan 18F-Fluciclovine PET/CT of PSA-Negative Prostate Cancer Bone Metastases. Clin Nucl Med 44(4):337-338, 2019. e-Pub 2019. PMID: 30688749.
Lu Y, Sweiss NJ, Macapinlac HA. Prognostic Impact of FDG-PET/CT Images in Patients With Suspected Cardiac Sarcoidosis: Optimal Patient Preparation, Not Complex Unconventional Analytics, Is Key to Meaningful Data. JACC Cardiovasc Imaging 12(1):217-219, 2019. e-Pub 2019. PMID: 30621993.
Etchebehere E, Brito AE, Kairemo K, Rohren E, Araujo J, Macapinlac HA. Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?. Radiol Bras 52(1):33-40, 2019. e-Pub 2019. PMID: 30804613.
Kairemo K, Rohren EM, Anderson PM, Ravizzini G, Rao A, Macapinlac HA, Subbiah V. Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. ESMO Open 4(1):e000439, 2019. e-Pub 2019. PMID: 30962954.
Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF. Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res 24(10):2304-2311, 2018. e-Pub 2018. PMID: 29476021.
Castello A, Macapinlac HA, Lopci E, Santos EB. Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. e-Pub 2018. PMID: 29785515.
Kairemo K, Milton DR, Etchebehere E, Rohren EM, Macapinlac HA. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience. Curr Radiopharm 11(2):147-152, 2018. e-Pub 2018. PMID: 29956640.
Lu Y, Chasen BA, Macapinlac HA. Imaging Characteristics of Chemotherapy Related Adult-Onset Still Disease. Clin Nucl Med 42(12):980-982, 2017. e-Pub 2017. PMID: 29076903.
Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging 44(6):969-978, 2017. e-Pub 2017. PMID: 27942837.
Chism CB, Ravizzini GC, Macapinlac HA, Pan T. Quantitative comparison between regularized time-of-flight and OSEM PET reconstructions for small 18F-FDG-avid lesions. Nucl Med Commun 38(6):529-536, 2017. e-Pub 2017. PMID: 28383318.
Kairemo K, Ravizzini GC, Macapinlac HA, Subbiah V. An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma. Diagnostics (Basel) 7(2), 2017. e-Pub 2017. PMID: 28375169.
Erwin WD, Jessop AC, Mar MV, Macapinlac HA, Mawlawi OR. Qualitative and quantitative comparison of gated blood pool single photon emission computed tomography using low-energy high-resolution and SMARTZOOM collimation. Nucl Med Commun 38(1):35-43, 2017. e-Pub 2017. PMID: 27775993.
Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac HA, Meza J, Hankins J, Mottaghy F, Juweid M, Quon A. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. Radiology 280(1):150689, 2016. e-Pub 2016. PMID: 26854705.
Etchebehere EC, Fox P, Milton D, Macapinlac HA, Rohren E. Reply: Prediction vs. Prognostication and Guarantee-Time Bias: Steering Clear of the Pitfalls of Interpreting Observational Data. J Nucl Med 57(6):991, 2016. e-Pub 2016. PMID: 27081171.
Etchebehere EC, Hobbs BP, Milton DR, Malawi O, Patel S, Benjamin RS, Macapinlac HA. Assessing the role of (18)F-FDG PET and (18)F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 43(5):860-70, 2016. e-Pub 2016. PMID: 26631240.
Macapinlac HA, Larson SM. In Memoriam: Edwaldo E. Camargo, MD 1938-2016. J Nucl Med 57(5):14N, 2016. e-Pub 2016. PMID: 27141024.
Etchebehere EC, Araujo JC, Milton DR, Erwin WD, Wendt RE, Swanston NM, Fox P, Macapinlac HA, Rohren EM. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. Clin Nucl Med. e-Pub 2016. PMID: 26828141.
Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging 43(1):8-20, 2016. e-Pub 2016. PMID: 26416392.
Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer 51(17):2545-52, 2015. e-Pub 2015. PMID: 26321501.
Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, Moody T, Macapinlac HA. DETERMINATION OF SKELETAL TUMOR BURDEN ON 18F-FLUORIDE PET/CT. J Nucl Med 56(10):1507-12, 2015. e-Pub 2015. PMID: 26135112.
Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic factors in patients treated with radium-223: the role of skeletal tumor burden on baseline 18F-fluoride-PET/CT in predicting overall survival. J Nucl Med 56(8):1177-84, 2015. e-Pub 2015. PMID: 26069307.
Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?. J Thorac Oncol 9(8):1202-6, 2014. e-Pub 2014. PMID: 25157774.
Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL, Macapinlac HA, Chuang HH. Impact of (18)F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging. e-Pub 2014. PMID: 24990404.
Takeuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett RL, Macapinlac HA. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 41(5):906-14, 2014. e-Pub 2014. PMID: 24442598.
Takeuchi S, Lucchini M, Schmeler KM, Coleman RL, Gershenson DM, Munsell MF, Macapinlac HA, Ramirez PT. Utility of (18)F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. Gynecol Oncol 133(1):100-4, 2014. e-Pub 2014. PMID: 24534359.
Khiewvan B, Macapinlac HA, Lev D, McCutcheon IE, Slopis JM, Al Sannaa G, Wei W, Chuang HH. The value of (18)F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors. Eur J Nucl Med Mol Imaging. e-Pub 2014. PMID: 24699907.
Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Kim SK, Videtic G, Neumann DR, Komaki R, Macapinlac HA, Bradley JD, Alavi A. Prediction of Survival by [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial. J Clin Oncol 31(30):3823-30, 2013. e-Pub 2013. PMID: 24043740.
Frumovitz M, Querleu D, Gil-Moreno A, Morice P, Jhingran A, Munsell MF, Macapinlac HA, Leblanc E, Martinez A, Ramirez PT. Lymphadenectomy in Locally Advanced Cervical Cancer Study (LiLACS): A phase III clinical trial comparing surgical to radiologic staging in patients with stages IB2-IVA cervical cancer. J Minim Invasive Gynecol. e-Pub 2013. PMID: 23911560.
Bhosale P, Balachandran A, Vikram R, Viswanathan C, Macapinlac HA, Rohren E, Prativadi R. What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?. Int J Mol Imaging 2013:476786, 2013. e-Pub 2013. PMID: 24455242.
Tateishi U, Terauchi T, Akashi-Tanaka S, Kinoshita T, Kano D, Daisaki H, Murano T, Tsuda H, Macapinlac HA. A comparative study on the value of dual tracer PET/CT to evaluate breast cancer. (18) F-FDG PET/CT images reveal a focal hypermetabolic focus of the primary tumor (upper panel), whereas (11) C-choline PET/CT images reveal only a focal hypermetabolic focus in the primary tumor (lower panel). Cancer Sci 103(9):Septembercover, 2012. e-Pub 2012. PMID: 22938535.
Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. e-Pub 2012. PMID: 22831985.
Frumovitz M, Ramirez PT, Macapinlac HA, Klopp AH, Nick AM, Ramondetta LM, Jhingran A. Anatomic Location of PET-Positive Aortocaval Nodes in Patients with Locally Advanced Cervical Cancer: Implications for Surgical Staging. Int J Gynecol Cancer. e-Pub 2012. PMID: 22810967.
Erasmus JJ, Macapinlac HA. Low-sensitivity FDG-PET studies: less common lung neoplasms. Semin Nucl Med 42(4):255-60, 2012. e-Pub 2012. PMID: 22681674.
Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. e-Pub 2012. PMID: 22586182.
Tateishi U, Terauchi T, Akashi-Tanaka S, Kinoshita T, Kano D, Daisaki H, Murano T, Tsuda H, Macapinlac HA. A Comparative Study on the Value of Dual Tracer PET/CT to Evaluate Breast Cancer. Cancer Sci. e-Pub 2012. PMID: 22632272.
Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 2012. e-Pub 2012. PMID: 22371887.
Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, Macapinlac HA. Neoadjuvant Chemotherapy in Breast Cancer: Prediction of Pathologic Response with PET/CT and Dynamic Contrast-enhanced MR Imaging--Prospective Assessment. Radiology 263(1):53-63, 2012. e-Pub 2012. PMID: 22438441.
Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4823-33, 2011. e-Pub 2011. PMID: 21456015.
Jackson J, Pan T, Tonkopi E, Swanston N, Macapinlac HA, Rohren EM. Implementation of Automated Tube Current Modulation in PET/CT: Prospective Selection of a Noise Index and Retrospective Patient Analysis to Ensure Image Quality. J Nucl Med Technol 39(2):83-90, 2011. e-Pub 2011. PMID: 21565950.
Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer1: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 117(9):1928-34, 2011. e-Pub 2011. PMID: 21509770.
Leibold T, Akhurst TJ, Chessin DB, Yeung HW, Macapinlac HA, Shia J, Minsky BD, Saltz LB, Riedel E, Mazumdar M, Paty PB, Weiser MR, Wong WD, Larson SM, Guillem JG. Evaluation of (18)F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis. Ann Surg Oncol. e-Pub 2011. PMID: 21476107.
Dickinson RL, Erwin WD, Stevens DM, Bidaut LM, Mar MV, Macapinlac HA, Wendt RE. Hybrid Modality Fusion of Planar Scintigrams and CT Topograms to Localize Sentinel Lymph Nodes in Breast Lymphoscintigraphy: Technical Description and Phantom Studies. Int J Mol Imaging 2011:298102, 2011. e-Pub 2011. PMID: 21490727.
Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer1: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. e-Pub 2010. PMID: 21082702.
Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. Int J Radiat Oncol Biol Phys 78(3):667-74, 2010. e-Pub 2010. PMID: 20171802.
Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer 116(19):4487-94, 2010. e-Pub 2010. PMID: 20629031.
Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg 90(3):884-90; discussion 890-1, 2010. e-Pub 2010. PMID: 20732513.
Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 16(9):1187-211, 2010. e-Pub 2010. PMID: 20558311.
Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer 20(6):936-44, 2010. e-Pub 2010. PMID: 20683399.
De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 51(8):1213-8, 2010. e-Pub 2010. PMID: 20660382.
Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The Standardized Uptake Value of 18-Fluorodeoxyglucose Positron Emission Tomography after Chemoradiation and Clinical Outcome in Patients with Localized Gastroesophageal Carcinoma. Oncology 78(5-6):316-322. e-Pub 2010. PMID: 20699623.
Kei PL, Vikram R, Yeung HW, Stroehlein JR, Macapinlac HA. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. AJR Am J Roentgenol 194(5):W401-6, 2010. e-Pub 2010. PMID: 20410385.
Núñez R, Erwin WD, Wendt RE, Stachowiak A, Mar M, Stevens D, Madewell JE, Yeung HW, Macapinlac HA. Acquisition Parameters for Oncologic Imaging with a New SPECT/Multislice CT Scanner. Mol Imaging Biol 12(2):110-38, 2010. e-Pub 2010. PMID: 20049543.
De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 21(1):33-9, 2010. e-Pub 2010. PMID: 19602564.
Tonkopi E, Chi PC, Mawlawi O, Riegel AC, Rohren EM, Macapinlac HA, Pan T. Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients. J Appl Clin Med Phys 11(1):3073, 2010. e-Pub 2010. PMID: 20160693.
Macapinlac HA, Czernin J, Larson SM. Practice Based Evidence of the Beneficial Impact of PET in Patients with Brain Tumors. Mol Imaging Biol 13(1):1-2, 2010. e-Pub 2010. PMID: 21082268.
Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac HA, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 115(22):5184-92, 2009. e-Pub 2009. PMID: 19685531.
Schechter NR, Erwin WD, Yang DJ, Kim EE, Munden RF, Forster K, Taing LC, Cox JD, Macapinlac HA, Podoloff DA. Radiation dosimetry and biodistribution of (99m)Tc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 36(10):1583-91, 2009. e-Pub 2009. PMID: 19396440.
Podoloff DA, Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ, Siegel BA, Singhal S, Tyler DS, Wong RJ. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 7 Suppl 2:S1-26, 2009. e-Pub 2009. PMID: 19555588.
Chuang HH, Macapinlac HA. The evolving role of PET-CT in the management of esophageal cancer. Q J Nucl Med Mol Imaging 53(2):201-9, 2009. e-Pub 2009. PMID: 19293768.
Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective Risk-Adjusted [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. J Clin Oncol 27(15):2509-15, 2009. e-Pub 2009. PMID: 19332725.
Macapinlac HA, Segall G. Continuously Improving PET Utilization. J Nucl Med 50(5):22N-5N, 2009. e-Pub 2009. PMID: 19403875.
De Giorgi U, Valero V, Rohren E, Shaheenah D, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche Jr HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating Tumor Cells and [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. J Clin Oncol 27(20):3303-11, 2009. e-Pub 2009. PMID: 19451443.
Rohren EM, Macapinlac HA. PET Imaging of Prostate Cancer: Other Tracers. PET Clin 4(2):185-92, 2009. e-Pub 2009. PMID: 27157010.
Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, Raymond AK, Lewis VO, Anderson PM, Bassett RL, Harrell RK, Marom EM. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med 50(3):340-7, 2009. e-Pub 2009. PMID: 19258257.
Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Inoue T, Macapinlac HA. Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT. Eur J Nucl Med Mol Imaging 36(6):894-902, 2009. e-Pub 2009. PMID: 19156410.
Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, Yang WT. Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data. J Nucl Med 50(2):231-8, 2009. e-Pub 2009. PMID: 19164229.
Vikram R, Yeung HD, Macapinlac HA, Iyer RB. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. AJR Am J Roentgenol 191(5):1545-51, 2008. e-Pub 2008. PMID: 18941099.
Macapinlac HA, Segall G. Building a Foundation for Better PET Utilization. J Nucl Med 49(9):46N-56N, 2008. e-Pub 2008. PMID: 18765584.
Chi PC, Mawlawi O, Luo D, Liao Z, Macapinlac HA, Pan T. Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation. Int J Radiat Oncol Biol Phys 71(3):890-9, 2008. e-Pub 2008. PMID: 18514781.
Reed VK, Cavalcanti JL, Strom EA, Perkins GH, Oh JL, Tereffe W, Yu TK, Yeung H, Whitman GJ, Bedrosian I, Macapinlac HA, Buchholz TA, Woodward WA. Risk of Subclinical Micrometastatic Disease in the Supraclavicular Nodal Bed According to the Anatomic Distribution in Patients with Advanced Breast Cancer. Int J Radiat Oncol Biol Phys 71(2):435-40, 2008. e-Pub 2008. PMID: 18164831.
Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 2008. e-Pub 2008. PMID: 18564354.
Schwartz DL, Macapinlac HA, Weber RS. FDG-PET staging of head and neck cancer--can improved imaging lead to improved treatment?. J Natl Cancer Inst 100(10):688-9, 2008. e-Pub 2008. PMID: 18477798.
Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 247(1):189-96, 2008. e-Pub 2008. PMID: 18372468.
Anderlini P, Swanston N, Rashid A, Bueso-Ramos C, Macapinlac HA, Champlin RE. Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant 14(4):478-80, 2008. e-Pub 2008. PMID: 18342791.
Kazama T, Faria SC, Uchida Y, Ito H, Macapinlac HA. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med 22(2):111-4, 2008. e-Pub 2008. PMID: 18311535.
Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol 46(1):23-9, 2008. e-Pub 2008. PMID: 18297544.
Yang WT, Le-Petross HT, Macapinlac HA, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M. Inflammatory breast cancer: PET/CT, MRI, mammography and sonography findings. Breast Cancer Res Treat 109(3):417-26, 2008. e-Pub 2008. PMID: 17653852.
Yang WT, Lane DL, Le-Petross HT, Abruzzo LV, Macapinlac HA. Breast lymphoma: imaging findings of 32 tumors in 27 patients. Radiology 245(3):692-702, 2007. e-Pub 2007. PMID: 17911538.
Klopp AH, Chang JY, Tucker SL, Sulman EP, Balter PA, Liu HH, Bucci MK, Macapinlac HA, Komaki R, Cox JD. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 69(5):1409-16, 2007. e-Pub 2007. PMID: 17904303.
Erasmus JJ, Macapinlac HA, Swisher SG. Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer 110(10):2155-68, 2007. e-Pub 2007. PMID: 17896784.
Namwongprom S, Núñez RF, Yeung HW, Kim EE, Macapinlac HA. Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid. Exp Clin Endocrinol Diabetes 115(10):694-6, 2007. e-Pub 2007. PMID: 18058606.
Cavalcanti JL, Núñez RF, Yeung HW, Mehran RJ, Macapinlac HA. Incidental finding of prostate cancer and adenomatous colon polyp in a patient with lung cancer. Clin Nucl Med 32(11):871-3, 2007. e-Pub 2007. PMID: 18075426.
Núñez R, Yeung HW, Swanston NM, Macapinlac HA. FDG uptake in gall bladder in the PET and PET/CT scan of three oncology patients. Rev Esp Med Nucl 26(4):234-6, 2007. e-Pub 2007. PMID: 17662192.
Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 109(1):125-34, 2007. e-Pub 2007. PMID: 17146785.
Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C. We should desist using RECIST, at least in GIST. J Clin Oncol 25(13):1760-4, 2007. e-Pub 2007. PMID: 17470866.
Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 1;25(13):1753-9, 2007. e-Pub 2007. PMID: 17470865.
Iyer RB, Balachandran A, Bruzzi JF, Johnson V, Macapinlac HA, Munden RF. PET/CT and hepatic radiation injury in esophageal cancer patients. Cancer Imaging 7:189-94, 2007. e-Pub 2007. PMID: 18055293.
Won KS, Gayed I, Kim EE, Macapinlac HA. Juvenile fibroadenoma of the breast demonstrated on (111)In-octreotide SPECT and (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging 34(3):440, 2007. e-Pub 2007. PMID: 17119960.
Namwongprom S, Núñez R, Kim EE, Macapinlac HA. Tc-99m MDP bone scintigraphy and positron emission tomography/computed tomography (PET/CT) imaging in Erdheim-Chester disease. Clin Nucl Med 32(1):35-8, 2007. e-Pub 2007. PMID: 17179801.
Bruzzi JF, Truong MT, Marom EM, Mawlawi O, Podoloff DA, Macapinlac HA, Munden RF. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG. AJR Am J Roentgenol 187(4):1116-23, 2006. e-Pub 2006. PMID: 16985164.
Munden RF, Truong MT, Gladish GW, Podoloff DA, Mawlawi O, Broemeling LD, Bruzzi JF, Macapinlac HA. Interobserver and intraobserver variability of standardized uptake value measurements in non-small-cell lung cancer. J Thorac Imaging 21(3):205-12, 2006. e-Pub 2006. PMID: 16915065.
Podoloff DA, Macapinlac HA. PET and PET/CT in Management of the Lymphomas. PET Clin 1(3):243-50, 2006. e-Pub 2006. PMID: 27157363.
Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu TT, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol 1(5):478-86, 2006. e-Pub 2006. PMID: 17409902.
Santiago JF, Gonen M, Yeung H, Macapinlac HA, Larson S. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 50(1):61-7, 2006. e-Pub 2006. PMID: 16557205.
Bruzzi JF, Macapinlac HA, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 47(8):1267-73, 2006. e-Pub 2006. PMID: 16883004.
Pan T, Mawlawi O, Luo D, Liu HH, Chi PC, Mar MV, Gladish G, Truong M, Erasmus J, Jr, Liao Z, Macapinlac HA. Attenuation correction of PET cardiac data with low-dose average CT in PET/CT. Med Phys 33(10):3931-8, 2006. e-Pub 2006. PMID: 17089855.
Mawlawi O, Erasmus JJ, Munden RF, Pan T, Knight AE, Macapinlac HA, Podoloff DA, Chasen M. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol 186(2):308-19, 2006. e-Pub 2006. PMID: 16423932.
Mawlawi O, Erasmus JJ, Pan T, Cody DD, Campbell R, Lonn AH, Kohlmyer S, Macapinlac HA, Podoloff DA. Truncation artifact on PET/CT: impact on measurements of activity concentration and assessment of a correction algorithm. AJR Am J Roentgenol 186:1458-67, 2006. e-Pub 2006. PMID: 16632745.
Pawlik TM, Erasmus JJ, Truong MT, Macapinlac HA, Ross MI, Gershenwald JE. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. Am J Roentgenol 187(1):W117-9, 2006. e-Pub 2006. PMID: 16794124.
Trent JC, Ramdas L, Dupart J, Hunt K, Macapinlac HA, Taylor E, Hu L, Salvado A, Abbruzzese JL, Pollock R, Benjamin RS, Zhang W. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer 107(8):1898-908, 2006. e-Pub 2006. PMID: 16986125.
Macapinlac HA. FDG-PET in head and neck, and thyroid cancer. Chang Gung Med J 28(5):284-95, 2005. e-Pub 2005. PMID: 16086543.
Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 32(12):1406-11, 2005. e-Pub 2005. PMID: 16133379.
Phongkitkarun S, Varavithya V, Kazama T, Faria SC, Mar MV, Podoloff DA, Macapinlac HA. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose. World J Gastroenterol 11(46):7284-9, 2005. e-Pub 2005. PMID: 16437629.
Sasaki R, Komaki R, Macapinlac HA, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23(6):1136-43, 2005. e-Pub 2005. PMID: 15718309.
Macapinlac HA. FDG-PET in the evaluation of cervical cancer. Gynecol Oncol 99(3 Suppl 1):S171-2, 2005. e-Pub 2005. PMID: 16419203.
Yi JG, Marom EM, Munden RF, Truong MT, Macapinlac HA, Gladish GW, Sabloff BS, Podoloff DA. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology 236(1):271-5, 2005. e-Pub 2005. PMID: 15987980.
Truong MT, Erasmus JJ, Macapinlac HA, Marom EM, Mawlawi O, Gladish GW, Sabloff BS, Bruzzi JF, Munden RF. Integrated positron emission tomography/computed tomography in patients with non-small cell lung cancer: normal variants and pitfalls. J Comput Assist Tomogr 29(2):205-209, 2005. e-Pub 2005. PMID: 15772538.
Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, Castillo R, Mohan R, Liao Z, Macapinlac HA. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 46(9):1481-7, 2005. e-Pub 2005. PMID: 16157531.
Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, Vaporciyan AA, Walsh GL, Sabloff BS, Broemeling LD, Stevens CW, Pisters KM, Podoloff DA, Macapinlac HA. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg 129(6):1364-70, 2005. e-Pub 2005. PMID: 15942579.
Martinez-Roman S, Ramirez PT, Oh J, Viciedo MG, Macapinlac HA. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol 96(3):888-91, 2005. e-Pub 2005. PMID: 15721446.
Mawlawi O, Podoloff DA, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Macapinlac HA. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med 45(10):1734-42, 2004. e-Pub 2004. PMID: 15471842.
Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183(6):1619-28, 2004. e-Pub 2004. PMID: 15547201.
Gayed I, Vu T, Iyer R, Johnson M, Macapinlac HA, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45(1):17-21, 2004. e-Pub 2004. PMID: 14734662.
Truong MT, Erasmus JJ, Munden RF, Marom EM, Sabloff BS, Gladish GW, Podoloff DA, Macapinlac HA. Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR Am J Roentgenol 183(4):1127-32, 2004. e-Pub 2004. PMID: 15385319.
Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64(17):5913-9, 2004. e-Pub 2004. PMID: 15342366.
Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac HA, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101(18):1776-85, 2004. e-Pub 2004. PMID: 15386332.
Truong MT, Erasmus JJ, Macapinlac HA, Podoloff DA. Teflon injection for vocal cord paralysis: false-positive finding on FDG PET-CT in a patient with non-small cell lung cancer. AJR Am J Roentgenol 182(6):1587-9, 2004. e-Pub 2004. PMID: 15150014.
Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, Heelan RT, Macapinlac HA, Jung SH, Silvestri GA, Siegel BA, Rusch VW. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126(6):1943-1951, 2003. e-Pub 2003. PMID: 14688710.
Gayed I, Vu T, Johnson M, Macapinlac HA, Podoloff D. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 5(1):26-31, 2003. e-Pub 2003. PMID: 14499159.
Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 44(9):1407-1412, 2003. e-Pub 2003. PMID: 12960184.
Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac HA, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59(6):913-918, 2002. e-Pub 2002. PMID: 12031380.
Sanchez Salmon A, Nunez R, Yeung H, Healey J, Macapinlac HA. FGD PET in a patient with pseudofractures from osteomalacia. Rev Esp Med Nucl 21(1):34-35, 2002. e-Pub 2002. PMID: 11821000.
Yeung HW, Sanches A, Squire OD, Macapinlac HA, Larson SM, Erdi YE. Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter. Eur J Nucl Med Mol Imaging 29:61-66, 2002. e-Pub 2002. PMID: 11807608.
Etchebehere EC, Macapinlac HA, Gonen M, Humm K, Yeung HW, Akhurst T, Scher HI, Larson SM. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET. Q J Nucl Med 46(2):122-130, 2002. e-Pub 2002. PMID: 12114875.
Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, Humm JL, Squire OD, Chui CS, Larson SM, Yorke ED. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62:51-60, 2002. e-Pub 2002. PMID: 11830312.
Nunez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43(1):46-55, 2002. e-Pub 2002. PMID: 11801702.
Nehmeh SA, Erdi YE, Ling CC, Rosenzweig KE, Schoder H, Larson SM, Macapinlac HA, Squire OD, Humm JL. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med 43(7):876-881, 2002. e-Pub 2002. PMID: 12097456.
Turlakow A, Yeung HW, Pui J, Macapinlac HA, Liebovitz E, Rusch V, Goy A, Larson SM. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 161(7):1003-7, 2001. e-Pub 2001. PMID: 11295964.
Ramos CD, Chisin R, Yeung HW, Larson SM, Macapinlac HA. Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent a second primary tumor. Clin Nucl Med 26(3):193-197, 2001. e-Pub 2001. PMID: 11245108.
Turlakow A, Larson SM, Coakley F, Akhurst T, Gonen M, Macapinlac HA, Kelly W, Leibel S, Humm J, Scardino P, Scher H, Hricak H. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med 45(3):235-424, 2001. e-Pub 2001. PMID: 11788816.
Macapinlac HA. Clinical usefulness of FDG PET in differentiated thyroid cancer. J Nucl Med 42(1):77-8, 2001. e-Pub 2001. PMID: 11197984.
Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, Chisin R, Larson SM. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 28:155-164, 2001. e-Pub 2001. PMID: 11303885.
Imbriaco M, Akhurst T, Hilton S, Yeung HW, Macapinlac HA, Mazumdar M, Pace L, Kemeny N, Erdi Y, Cohen A, Fong Y, Guillem J, Larson SM. Whole-Body FDG-PET in Patients with Recurrent Colorectal Carcinoma. A Comparative Study with CT. Clin Positron Imaging 3(3):107-114, 2000. e-Pub 2000. PMID: 11008100.
McCaffrey JA, Reuter VV, Herr HW, Macapinlac HA, Russo P, Motzer RJ. Carcinoid tumor of the kidney. The use of somatostatin receptor scintigraphy in diagnosis and management. Urol Oncol 5(3):108-111, 2000. e-Pub 2000. PMID: 10765017.
Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac HA, Rosai J, Robbins RJ. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85(3):1107-13, 2000. e-Pub 2000. PMID: 10720047.
Nunez RF, Yeung HW, Macapinlac HA, Castro-Malaspina H, Larson SM. Ga-67 uptake in cutaneous lesions of graft-versus-host disease. Clin Nucl Med 25(9):676-678, 2000. e-Pub 2000. PMID: 10983752.
Erdi YE, Macapinlac HA, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, Yorke ED. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 27(7):861-866, 2000. e-Pub 2000. PMID: 10952499.
Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18(6):1173-1180, 2000. e-Pub 2000. PMID: 10715285.
Guillem JG, Puig-La Calle J, Jr, Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac HA, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 43(1):18-24, 2000. e-Pub 2000. PMID: 10813118.
Robbins RJ, Hill RH, Wang W, Macapinlac HA, Larson SM. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10(2):177-183, 2000. e-Pub 2000. PMID: 10718556.
Rini JN, Yeung HW, Nunez RF, la Calle JP, Larson S, Macapinlac HA. FDG-PET Patterns of Abdominal Carcinomatosis. Clin Positron Imaging 2(6):333, 1999. e-Pub 1999. PMID: 14516630.
Macapinlac HA, Yeung HW, Larson SM. Defining the Role of FDG PET in Head and Neck Cancer. Clin Positron Imaging 2(6):311-316, 1999. e-Pub 1999. PMID: 14516613.
Wang W, Macapinlac HA, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291-302, 1999. e-Pub 1999. PMID: 10404792.
Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging 2(3):159-171, 1999. e-Pub 1999. PMID: 14516540.
Macapinlac HA, Humm JL, Akhurst T, Osman I, Pentlow K, Shangde C, Yeung HW, Squire O, Finn RD, Scher HI, Larson SM. Differential Metabolism and Pharmacokinetics of L-[1-(11)C]-Methionine and 2-[(18)F] Fluoro-2-deoxy-D-glucose (FDG) in Androgen Independent Prostate Cancer. Clin Positron Imaging 2(3):173-181, 1999. e-Pub 1999. PMID: 14516541.
Fong Y, Saldinger PF, Akhurst T, Macapinlac HA, Yeung H, Finn RD, Cohen A, Kemeny N, Blumgart LH, Larson SM. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 178(4):282-287, 1999. e-Pub 1999. PMID: 10587184.
Nunez RF, Yeung HW, Macapinlac HA. Increased F-18 FDG uptake in the stomach. Clin Nucl Med 24:281-282, 1999. e-Pub 1999. PMID: 10466532.
Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in Esophageal Cancer. Incremental Value over Computed Tomography. Clin Positron Imaging 2:255-260, 1999. e-Pub 1999. PMID: 14516649.
Erdi YE, Macapinlac HA, Larson SM, Erdi AK, Yeung H, Furhang EE, Humm JL. Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. Clin Positron Imaging 2(1):41-46, 1999. e-Pub 1999. PMID: 14516552.
Adler ML, Macapinlac HA, Robbins RJ. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. Endocr Pract 4(5):282-286, 1998. e-Pub 1998. PMID: 15251726.
Sgouros G, O'Donoghue JA, Larson SM, Macapinlac H, Larson JJ, Kemeny N. Mathematical model of 5-[125I]iodo-2'-deoxyuridine treatment: continuous infusion regimens for hepatic metastases. Int J Radiat Oncol Biol Phys 41(5):1177-83, 1998. e-Pub 1998. PMID: 9719130.
Akhurst T, Boland P, Macapinlac HA, Finn R, Yeung HW, Squire O, Larson SM. Excess Muscle FDG Uptake in an Euglycaemic Patient That Is Corrected by Fasting. Clin Positron Imaging 1(2):131-133, 1998. e-Pub 1998. PMID: 14516602.
Yeung HW, Macapinlac HA, Karpeh M, Finn RD, Larson SM. Accuracy of FDG-PET in Gastric Cancer. Preliminary Experience. Clin Positron Imaging 1(4):213-221, 1998. e-Pub 1998. PMID: 14516555.
El-Shirbiny AM, Yeung H, Imbriaco M, Michaeli J, Macapinlac HA, Larson SM. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med 38(8):1208-1210, 1997. e-Pub 1997. PMID: 9255151.
Macapinlac HA, Larson SM. Positron emission tomography (PET)--measured biochemical response to radiotherapy of laryngeal tumors. Cancer J Sci Am 3(6):333-335, 1997. e-Pub 1997. PMID: 9403044.
Yeung H, Macapinlac HA. First impressions. A 21-yr-old woman with adenocarcinoma of the pelvis. What is the radiopharmaceutical? What are the findings?. J Nucl Med 37(12):7A, 1994, 1996. e-Pub 1996. PMID: 8999117.
Yeung HW, Imbriaco M, Zhang JJ, Macapinlac HA, Goldsmith SJ, Larson SM. Visualization of myocardial metastasis of carcinoid tumor by indium-111-pentetreotide. J Nucl Med 37(9):1528-30, 1996. e-Pub 1996. PMID: 8790210.
Macapinlac HA, Kemeny N, Daghighian F, Finn R, Zhang J, Humm J, Squire O, Larson SM. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med 37(4 Suppl):25S-29S, 1996. e-Pub 1996. PMID: 8676200.
Daghighian F, Humm JL, Macapinlac HA, Zhang J, Izzo J, Finn R, Kemeny N, Larson SM. Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver. J Nucl Med 37(4 Suppl):29S-32S, 1996. e-Pub 1996. PMID: 8676201.
Abdel-Dayem H, Bag R, Macapinlac HA, Elgazzar AH, Habbab N, Pescatore F, Kempf J. Diffuse Tl-201 uptake in the lungs. Etiologic classification and pattern recognition. Clin Nucl Med 20(2):164-72, 1995. e-Pub 1995. PMID: 7720309.
Reinsel RA, Veselis RA, Feshchenko VA, Di Resta GR, Mawlawi O, Beattie B, Silbersweig D, Stern E, Blasberg R, Macapinlac HA. Target detection and the prefrontal cortex. A PET scan study of the P300 event-related potential. Ann N Y Acad Sci 769:393-397, 1995. e-Pub 1995. PMID: 8595041.
Scott AM, Macapinlac HA, Zhang J, Daghighian F, Montemayor N, Kalaigian H, Sgouros G, Graham MC, Kolbert K, Yeh SD. Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer. J Nucl Med 36:100-103, 1995. e-Pub 1995. PMID: 7799059.
Caluser C, Scott A, Macapinlac HA, Yeh S, Rosenfelt N, Farid B, Abdel-Dayem HM, Larson SM, Kalaigian H. Extramedullary hematopoiesis assessment in a patient with osteopetrosis. Clin Nucl Med 20(1):75, 1995. e-Pub 1995. PMID: 7895447.
Larson, SM, Divgi, CR, Scott, AM, Daghighian, F, Macapinlac, HA, Welt, S. Current status of radioimmunodetection. Nucl Med Biol 215(5):721-729, 1994. e-Pub 1994. PMID: 9241648.
Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Seidman AD, Goldsmith SJ, Larson SM. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 35(11):1748-1752, 1994. e-Pub 1994. PMID: 7525900.
Scott AM, Macapinlac HA, Divgi CR, Zhang JJ, Kalaigian H, Pentlow K, Hilton S, Graham MC, Sgouros G, Pelizzari C, et al. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med 35(12):1976-84, 1994. e-Pub 1994. PMID: 7989980.
Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, Kothari P, Desai R, Zhang J, Beattie B, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med 35(14):1407-1418, 1994. e-Pub 1994. PMID: 8071684.
Caluser CI, Abdel-Dayem HM, Macapinlac HA, Scott A, Healey JH, Huvos A, Kalaigian H, Yeh SD, Larson SM. The value of thallium and three-phase bone scans in the evaluation of bone and soft tissue sarcomas. Eur J Nucl Med 21:1198-1205, 1994. e-Pub 1994. PMID: 7859771.
Macapinlac HA, Scott AM, Larson SM, Divgi CR, Yeh SD, Goldsmith SJ. Gallium-67-citrate imaging in nuclear oncology. Nucl Med Biol 21(5):731-738, 1994. e-Pub 1994. PMID: 9241649.
Rusch V, Macapinlac HA, Heelan R, Kramer E, Larson S, McCormack P, Burt M, Martini N, Ginsberg R. NR-LU-10 monoclonal antibody scanning. A helpful new adjunct to computed tomography in evaluating non-small-cell lung cancer. J Thorac Cardiovasc Surg 106(2):200-4, 1993. e-Pub 1993. PMID: 8393504.
Daghighian F, Pentlow KS, Larson SM, Graham MC, DiResta GR, Yeh SD, Macapinlac HA, Finn RD, Arbit E, Cheung NK. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med 20(5):402-9, 1993. e-Pub 1993. PMID: 8519259.
Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Sonenberg M, Goldsmith SJ, Larson SM. Hiatal hernia on whole-body radioiodine survey mimicking metastatic thyroid cancer. Clin Nucl Med 18(9):751-753, 1993. e-Pub 1993. PMID: 8403716.
Roistacher N, Preminger M, Macapinlac HA, Pierri MK. Myocardial entrapment by lymphoma: a cause of reversible segmental left ventricular dysfunction. Am Heart J 124(2):516-521, 1992. e-Pub 1992. PMID: 1636600.
Caluser C, Macapinlac HA, Healey J, Ghavimi F, Meyers P, Wollner N, Kalaigian J, Kostakoglu L, Abdel-Dayem HM, Yeh SD, et al. The relationship between thallium uptake, blood flow, and blood pool activity in bone and soft tissue tumors. Clin Nucl Med 17(7):565-72, 1992. e-Pub 1992. PMID: 1638838.
Caluser C, Healey J, Macapinlac HA, Kostakoglu L, Abdel-Dayem HM, Larson SM, Yeh SD. Thallium uptake in recurrent pigmented villonodular synovitis. Correlation with three-phase bone scanning. Clin Nucl Med 17(9):751-3, 1992. e-Pub 1992. PMID: 1395357.
Hoener B, Engelstad BL, Ramos EC, Macapinlac HA, Price DC, Johnson TR, White DL. Comparison of Fe-HBED and Fe-EHPG as hepatobiliary MR contrast agents. J Magn Reson Imaging 1:357-62, 1991. e-Pub 1991. PMID: 1802149.

Invited Articles

Macapinlac HA, Larson SM. Positron Emission Tomography (PET)-measured biochemical response to radiotherapy of laryngeal tumors. Cancer J Sci Am 3(6):333-5, 1997. e-Pub 1997.
Abdel-Dayem HM, Scott A, Macapinlac HA, Larson S. Tracer imaging in lung cancer. Eur J Nucl Med (1):57-81, 1994. e-Pub 1994.
Macapinlac HA, Larson SM. Whole body PET in oncology. Oncology 7(7):52-55, 1993. e-Pub 1993.

Review Articles

Kairemo K, Gouda MA, Buschhorn L, Wahida A, Macapinlac, H, Anderson PM, Subbiah V. Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors. ESMO Open 8(4):101575, 2023. e-Pub 2023. PMID: 37517365.
Yadav D, Hwang H, Qiao W, Upadhyay R, Chapin BF, Tang C, Aparicio A, Lopez-Olivo MA, Kang SK, Macapinlac HA, Bathala TK, Surasi DS. 18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer 4(2):e210091, 2022. e-Pub 2022. PMID: 35212559.
Rohren EM, Macapinlac HA. Spectrum of Benign Bone Conditions on NaF-PET. Semin Nucl Med 47(4):392-396, 2017. e-Pub 2017. PMID: 28583278.
Macapinlac HA. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med 38(2):137-40, 2008. e-Pub 2008. PMID: 18243849.
Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, Iyer RB, Pan TS, Macapinlac HA, Erasmus JJ. PET/CT of esophageal cancer: its role in clinical management. Radiographics 27(6):1635-52, 2007. e-Pub 2007. PMID: 18025508.
Podoloff DA, Macapinlac HA. PET and PET/CT in Management of the Lymphomas. Radiol Clin North Am 45(4):689-96, vii, 2007. e-Pub 2007. PMID: 17706533.
Mar MV, Miller SA, Kim EE, Macapinlac HA. Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT lymphoscintigraphic imaging. J Nucl Med Technol 35(1):10-6; quiz 17-20, 2007. e-Pub 2007. PMID: 17337652.
Bruzzi JF, Truong MT, Macapinlac HA, Munden RF, Erasmus JJ. Integrated CT-PET imaging of esophageal cancer: unexpected and unusual distribution of distant organ metastases. Curr Probl Diagn Radiol 36(1):21-9, 2007. e-Pub 2007. PMID: 17198889.
Macapinlac HA. Positron Emission Tomography of the Brain. PET Clin 2(1):1-13, 2007. e-Pub 2007. PMID: 27157702.
Munden RF, Macapinlac HA, Erasmus JJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging 21(2):137-45, 2006. e-Pub 2006. PMID: 16770230.
Mawlawi O, Pan T, Macapinlac HA. PET/CT imaging techniques, considerations, and artifacts. J Thorac Imaging 21(2):99-110, 2006. e-Pub 2006. PMID: 16770227.
Macapinlac HA. Positron emission tomography of the brain. Neuroimaging Clin N Am 16(4):591-603, 2006. e-Pub 2006. PMID: 17148021.
Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 25(1):191-207, 2005. e-Pub 2005. PMID: 15653595.
Frank SJ, Chao KS, Schwartz DL, Weber RS, Apisarnthanarax S, Macapinlac HA. Technology insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning. Nat Clin Pract Oncol 2(10):526-33, 2005. e-Pub 2005. PMID: 16205772.
Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 7(4):293-9, 2005. e-Pub 2005. PMID: 15946589.
Macapinlac HA. FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J 10:262-70, 2004. e-Pub 2004. PMID: 15383207.
Macapinlac HA. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma. Mol Imaging Biol 6(4):200-7, 2004. e-Pub 2004. PMID: 15262235.
Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac HA, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78(4):1152-60; discussion 1152-60, 2004. e-Pub 2004. PMID: 15464463.
Chisin R, Macapinlac HA. The indications of FDG-PET in neck oncology. Radiol Clin North Am 38(5):999-1012, 2000. e-Pub 2000. PMID: 11054965.
Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. Endocr Pract 6(6):460-464, 2000. e-Pub 2000. PMID: 11155220.
Goldsmith SJ, Macapinlac HA, O'Brien JP. Somatostatin receptor imaging in lymphoma. Semin Nucl Med 25(3):262-271, 1995. e-Pub 1995. PMID: 7570045.
Abdel-Dayem HM, Scott A, Macapinlac HA, Larson S. Tracer imaging in lung cancer. Eur J Nucl Med 21(1):57-81, 1994. e-Pub 1994. PMID: 8088287.
Scott AM, Macapinlac HA, Zhang JJ, Kalaigian H, Graham MC, Divgi CR, Sgouros G, Goldsmith SJ, Larson SM. Applications of fusion imaging in oncology. Nucl Med Biol 21(5):775-784, 1994. e-Pub 1994. PMID: 9241654.
Larson SM, Macapinlac HA, Scott AM, Divgi CR. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. Acta Oncol 32(7/8):709-715, 1993. e-Pub 1993. PMID: 8305216.

Professional Educational Materials

Larson SM, Macapinlac HA, Shankar LK. RSP2907RC - Molecular Imaging in Oncology (2008). RSNA, 2008.
Macapinlac HA. Cardinal Health: PET Champions Series Home Study CD: PET in Radiation Planning, PET in Head/Neck Cancer, PET in Lung Cancer, 2007.
Macapinlac HA. Educational Symposia DVD: 2005 PET-CT Imaging in Clinical Practice & PET-CT for Radiation Therapy, 2005.
Macapinlac HA. GE Healthcare Videotape/CD: PET Oncology Fundamentals for Reading & Referring Physicians, 2001.
Larson SM, Macapinlac HA, Yeung HWD, Rigo P. Clinical PET in Oncology. Williams & Wilkins, 1996.

Editorials

Lu Y, Sweiss NJ, Macapinlac HA. What Is the Optimal Method on Myocardial Suppression in FDG PET/CT Evaluation of Cardiac Sarcoidosis?. Clin Nucl Med 46(11):904-905, 2021. PMID: 34132675.

Abstracts

Kairemo KJ, Jessop A, Kappadath SC, Macapinlac HA. A prospective comparative study of using ultrasonography (US), 4D-CT and parathyroid dual-phase scintigraphy with SPECT in patients with primary hyperparathyreoidism. SNMMI Annual Meeting 2016, 2016. e-Pub 2016.
Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 after neoadjuvant therapy and surgery for esophageal cancer: an orphan status. 46th Annual Meeting Program, The Society of Thoracic Surgeons(44):174-175, 2010. e-Pub 2010.
Yoo DC, Hillman S, Macapinlac HA, Fernando H, Rilling WS, Shepard JO, et al. F-18 FDC PET/CT in Stage 1A NSCLC after RFA: Initial Report from a Cooperative Group Trial - American College of Surgeons Oncology Group Z4033. RSNA 2009 Scientific Assembly and Annual Meeting Program:688, 2009. e-Pub 2009.
Jackson J, Smith A, Pan T, Swanston N, Rohren E, Macapinlac H. Bismuth shielding: Evaluation of benefits and effects on PET/CT acquisition. J Nucl Med 49:422P, 2008. e-Pub 2008.
Pan T, Gould L, Mawlawi O, Gladish, Rohren E, Macapinlac H. Assessment of heart motion during respiration with cine CT without gating in cardiac PET. J Nucl Med 49:384P, 2008. e-Pub 2008.
Chang T, Pan T, Riegel A, Chang G, Rohren E, Macapinlac H, Mawlawi O. Comparison of internal target volumes for treatment planning using CT and PET. J Nucl Med 49:325P, 2008. e-Pub 2008.
Chang T, Pan T, Chang G, Rohren E, Macapinlac H, Mawlawi O. Effects of scan duration and count density on the quantitative accuracy of PET images. J Nucl Med 49:395P, 2008. e-Pub 2008.
Pan T, Gould L, Mawlawi O, Mar M, Rohren E, Macapinlac H. Investigation of helical CT with rigid body translation for attenuation correction of cardiac PET data. J Nucl Med 49:390P, 2008. e-Pub 2008.
Jackson J, Smith A, Swanston N, Chasen B, Fitzgerald N, Rohren E, Macapinlac H. Bismuth shielding: A tool to reduce CT dose to female pediatric breast tissue during PET/CT acquisition, while not compromising image data. J Nucl Med 59:416P, 2008. e-Pub 2008.
Riegel A, Mawlawi O, Rohren E, Macapinlac H, Pan T. Determination of PET thresholds for solitary pulmonary tumors in radiation treatment planning. J Nucl Med 49:382P, 2008. e-Pub 2008.
Mawlawi O, Yahil A, Vija H, Erwin W, Macapinlac H. Reduction in scan duration or injected dose in planar bone scintigraphy enabled by Pixon® post-processing. J Nucl Med 48:13P-b, 2007. e-Pub 2007.
Tonkopi E, Mawlawi O, Chi PC, Yeung H, Macapinlac H, Pan T. Effect of Average CT on quantifying PET images of colorectal cancer metastasis in the liver. J Nucl Med 48:411P-a, 2007. e-Pub 2007.
Jackson J, Pan T, Swanston N, Macapinlac H, Podoloff D, Mawlawi O. Effects of detector malfunction on PET quantification accuracy. J Nucl Med 48:462P, 2007. e-Pub 2007.
Chi PC, Mawlawi O, Yeung H, Macapinlac H, Pan T. Effect of average CT on quantifying PET images of lung cancer. J Nucl Med 48:96P, 2007. e-Pub 2007.
Jackson J, Pan T, Swanston N, Macapinlac H, Podoloff D. Strategy to reduce CT dose and maintain image quality for small body habitus patients in PET/CT. J Nucl Med 48:450P-b, 2007. e-Pub 2007.
Mawlawi O, Erwin W, Pan T, Wendt III R, Chasen B, Nunez R, Yeung H, Macapinlac H. What is the optimal minimum whole body bone SPECT scan duration that can replace planar bone scintigraphy?. J Nucl Med 48:120P-c, 2007. e-Pub 2007.
Mawlawi O, Truong M, Marom E, Pan T, Sabloff B, Bruzzi J, Erasmus J, Yeung H, Macapinlac H. Clinical evaluation of 2D versus 3D whole body FDG imaging performed on two PET scanners with different detectors. J Nucl Med 48:442P-a, 2007. e-Pub 2007.
Mar MV, Miller SA, Kim, EE, Macapinlac HA. Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT. J Nucl Med 35(1):10-16, 2007. e-Pub 2007.
Dickinson R, Mar M, Erwin W, Bidaut L, Mawlawi O, Macapinlac H, Wendt R. Investigation of a novel approach to localizing the sentinel node in breast lymphoscintigraphy: Fusion of planar scintigrams and CT topograms. J Nucl Med 48:425P-a, 2007. e-Pub 2007.
Nunez R, Namwongprom S, Stachowiak A, Mar M, Yeung H, Macapinlac H. Added value of SPECT/Multislice CT over diagnostic whole body planar imaging in patients with thyroid carcinoma. J Nucl Med 48:266P-a, 2007. e-Pub 2007.
Mawlawi O, Pan T, Qiao F, Devaraju V, Lofton B, Truong M, Macapinlac H. How long should gated PET/CT scans be in order to generate individual images with good quality??. J Nucl Med 47:388P-b, 2006. e-Pub 2006.
Pan T, Hamill J, Luo D, Mawlawi O, Macapinlac H. PET imaging of the thorax with attenuation correction by time-averaging and attenuation-averaging of CT data from 4DCT. J Nucl Med 47:192P-b, 2006. e-Pub 2006.
Mawlawi O, Pan T, Baghaei H, Swanston N, Darensborg B, Erasmus J, Macapinlac H. A comparison of lesion detectability among four different PET scanners. J Nucl Med 47(366P-a), 2006. e-Pub 2006.
Pan T, Mawlawi O, Nehmeh S, Erdi Y, Chi PC, Luo D, Truong M, Erasmus J, Macapinlac H. Attenuation correction of cardiac PET data with respiration-averaged CT on PET/CT data with respiration-averaged CT on PET/CT. J Nucl Med 47(385P-a), 2006. e-Pub 2006.
Mawlawi O, Erwin W, Pan T, Bartosh J, Kim E, Macapinlac H. Can whole body bone SPECT replace planar imaging when acquired over a similar duration?. J Nucl Med 47:62P-a, 2006. e-Pub 2006.
Pan T, Mawlawi O, Nehmeh S, Erdi Y, Chi P, Luo D, Truong M, Erasmus J, Macapinlac H. New low dose cine CT for quantitation of the PET data in the thorax on PET/CT. J Nucl Med 47:395P, 2006. e-Pub 2006.
Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, Castillo R, Mohan R, Liao Z, Macapinlac HA. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 46(9):1481-1487, 2005. e-Pub 2005.
Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of F18-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45(1):17-21, 2004. e-Pub 2004.
Mawlawi O, Podoloff DA, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Macapinlac HA. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med 45(10):1734-1742, 2004. e-Pub 2004.
Mawlawi O, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Podoloff DA, Macapinlac HA. Performance characteristics of the GE discovery ST PET/CT scanner using the nema standard. J Nucl Med 44(5):111p, 2003. e-Pub 2003.
Varavithya V, Phongkitkarun S, Kazama T, Faria SC, Mar M, Podoloff DA, Macapinlac HA. FDG-PET in Lymphoma of the liver: Lesion detection by FDG-PET vs. CT. J Nucl Med 44(5):83P, 2003. e-Pub 2003.
Turkakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal Carcinomatosis: Role of (18)F-FDG PET. J Nucl Med 44(9):1407-9, 2003. e-Pub 2003.
Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Granulocyte colony stimulating factor: an investigation on increased uptake and optimal length of time for diagnosis when used with F-18 FDG PET. J Nucl Med 44(5):187p, 2003. e-Pub 2003.
Forster KM, Mawlawi O, Cody D, Steadham RE, Chao C, Guerrero R, Komaki R, Kohlmyer S, Macapinlac H. Identification of acceptance criteria and testing of a PET/CT scanner for radiotherapy treatment planning. J Nucl Med 44 (Suppl)(5):291p, 2003. e-Pub 2003.
Gayed I, Vu T, Johnson M, Macapinlac HA, Podoloff DA. Comparison of bone and 2-deoxy-2-(18F) fluoroglucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 5(1):26-31P, 2003. e-Pub 2003.
Mawlawi O, Kohlmyer S, Podoloff DA, Macapinlac H. Evaluation of clinical image quality and lesion detectability of the discovery ST (DST) PET/CT scanner. J Nucl Med 44 (Suppl)(5):282p, 2003. e-Pub 2003.
Phongkitkarun S, Varavithya V, Kazama T, Faria SC, Mar M, Podoloff DA, Macapinlac HA. Lymphomatous involvement of the gastrointestinal tract: evaluation by positron emission tomography (PET) with 18F-Fluorodeoxyglucose (18F-FDG). J Nucl Med 44(5):83p, 2003. e-Pub 2003.
Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen-Forster K, Roth J, Putnam JB, Moran C, Cox JD. SUV by FDG-PET predicts outcome of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 57 (Suppl)(2):S166, 2003. e-Pub 2003.
Gayed I, Sureshbabu W, Iyer R, Macapinlac H Johnson M, Podoloff DA. Positron emission tomography versus computerized tomography for identification of melanoma metastases. J Nucl Med 43(1187):294P, 2002. e-Pub 2002.
Yang DJ, Macapinlac HA, Yu D, Azhdarinia A, Kohanim S, Bryant JL, Kim EE, Podoloff DA. Glucosamine pathway imaging using 99mTc-EC-deoxyglucose in comparison with 18F-FDG. J Nucl Med 43(1478):368P, 2002. e-Pub 2002.
Ozaki K, Yang DJ, Macapinlac HA, Yu D, Kohanim S, Kim EE, Podoloff DA. 18F-Fluoropenciclovir for PET assessment of HSV-TK reporter gene expression and localization. J Nucl Med 42(1109):274P, 2002. e-Pub 2002.
Gayed I, Vu T, Macapinlac HA. Comparison of bone and F-18 FDG scans in the evaluation of bony metastases. J Nucl Med 43(Suppl):285P, 2002. e-Pub 2002.
Macapinlac HA, Podoloff DA, Swanston N, Acoy D, Mawlawi O, Champagne J. Utility of FDG PET in identifying richters transformation in patients with chronic lymphocytic leukemia (CLL). J Nucl Med 43(108):30P, 2002. e-Pub 2002.
Nehmeh SA, Ford E, Macapinlac HA, Larson SM, Mageras G, Yorke E, Humm J, Sidhu K, Pentlow K, Squire O, Yusef E. Gated positron emission tomography: A technique for reducing lung tumor motion effect. J Nucl Med 42(124):34P, 2001. e-Pub 2001.
Yeung HW, Erdi Y, Squire O, Macapinlac HA, Larson SM. Standardized uptake value normalized to body surface area (SUVBSA) for pediatric patients. J Nucl Med 42(815):189P, 2001. e-Pub 2001.
Santiago JF, Macapinlac HA, Yeung H, Larson SM. The uptake of 18F-FDG PET scans in the management of 133 breast cancer patients. J Nucl Med 42(1236):297P, 2001. e-Pub 2001.
Erdi YE, Yorke ED, Erdi AK, Hu YC, Braban LE, Macapinlac H, Humm JL, Squire OD, Larson SM, Chui CS, Rosenzweig K. The role of PET in radiotherapy treatment planning for patients with non-small cell lung cancer (NSCLC). J Nucl Med 42(1255):302P, 2001. e-Pub 2001.
Machac J, Zhang Z, Nunez R, Chen WT, Macapinlac HA, Larson SM. 18F Fluorodeoxyglucose uptake in human thoracic aortas assessed in vivo by positron emission tomography. J Nucl Med 42(201):54P, 2001. e-Pub 2001.

Book Chapters

Virarkar, M, Macapinlac, HA, Pokhylevych, H, Bhosale, PR. Chapter 5: Assessing Response to Therapy. In: Oncologic Imaging: A Multidisciplinary Approach. 2nd. Elsevier, 28-38, 2022.
Lin, M, Le, DB, Macapinlac, HA. New PET radiopharmaceuticals for cancer imaging, 557-564, 2022.
Kairemo, K, Macapinlac, HA. Oncology, bone metastases, 408-425, 2022.
Kairemo, K, Macapinlac, HA. Treatment Response Evaluation of Bone Metastases Using 18F-NaF, 101-117, 2021.
Macapinlac HA. Imaging of Interventional Therapies in Oncology: Positron Emission Tomography/Computed Tomography. In: Image-Guided Cancer Therapy: A Multidisciplinary Approach. Springer, 267-276, 2013.
Macapinlac HA. Assessing Response to Therapy. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier Saunders, 25-33, 2012.
Rohren EM, Macapinlac HA. PET Imaging of Prostate Cancer: Other Tracers. In: PET Clinics. SAUNDERS, 185-192, 2009.
Abdel-Dayem HM, Scott AM, Macapinlac, HA. Thallium 201 Chloride: A Tumor Imaging Agent. In: Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingston, 71-81, 2004.
Macapinlac HA. FDG PET in Breast Cancer. In: Advanced Therapy of Breast Disease. BC Decker, 2004.
Macapinlac HA. The Role of PET in Planning Radiation Therapy and Monitoring It’s Effects. In: Nuclear Medicine Annual. Lippincott, Williams, & Wilkins, 163-173, 2004.
Macapinlac HA. Head and Neck Cancer. In: Principles and Practice of Positron Emission Tomography. Lippincott, Williams, & Wilkins, 2002.
Chisin R, Macapinlac HA. The Indications of FDG PET in Head and Neck Oncology. In: Radiol Clin North Am, 999-1012, 2000.
Macapinlac HA. Hepatic Artery Pump Evaluation Prior to Locoregional Chemotherapy of Hepatic Metastases from Colorectal Cancer in Nuclear Medicine. In: test. Lippincott, Williams, and Wilkins, 2000.
Abdel-Dayem, HM, Macapinlac, HA. Malignant Lymphoma. In: Clinical Nuclear Medicine. Thomson Science & Professional, 517- 524, 1998.
Abdel-Dayem, HM, Macapinlac, HA. Thallium 201 Chloride, A Tumor Imaging Agent. In: Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingston, 831-842, 1998.
Macapinlac HA. The Role of Nuclear Medicine in the Diagnosis and Treatment of Liver Metastases from Colorectal Carcinoma. In: Nuclear Medicine Annual. Lippincott-Raven Publishers, 163-179, 1997.
Finn, R, Macapinlac, HA, Humm, J, Pentlow, K, McDevitt, M, Tjuvajev, JBlasberg, R, Scheinberg, D, Larson, SM, Zweit, J. Application of PET radionuclides for nuclear medicine targeted therapies. In: Application of accelerators in research and industry: Proceedings of the 14th International Conference. American Institute of Physics, 1345-1347, 1996.
Finn, RD, Divgi, CR, Goldsmith, SJ, Larson, SM, Macapinlac, HA, Scott, AM, Yeh, SDJ. Radionuclides and their application to oncology research. In: Chemists’ views of imaging centers. Plenum Press, 277-284, 1995.
Abdel-Dayem, HM, Macapinlac, HA, Larson, SM, Scott, AM. Adult malignancy: thallium scintigraphy. In: Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingston, 727-735, 1994.
Abdel-Dayem, HM, Scott, AM, Macapinlac, HA, El-Gazzar, AH, Larson, SM. Role of Thallium-201 Chloride and Tc-99m Sestamibi in Tumor Imaging. In: Nuclear Medicine Annual. Raven Press, 181-234, 1994.
Abdel-Dayem, HM, Macapinlac HA, Larson, SM. The role of thallium chloride in brain tumor imaging. In: Brain: Diagnosis and Radionuclides, Current Status and Future Aspects. Mediterrea, 81-88, 1992.

Books (edited and written)

Hofman, Michael S, Hicks, Rodney J. PET/CT in Melanoma. Springer, 2017.
Kayani, Irfan. PET/CT in Hodgkin's Lymphoma. Springer, 2017.
Seshadri, Nagabhushan, Eswar, Chinnamani. PET/CT in Cancer of Unknown Primary. Springer, 2017.
Du, Young. PET/CT in Colorectal Cancer. Springer, 2017.
Chua, Sue. PET/CT in Radiotherapy Planning. Springer, 2017.
Szyszko, Teresa. PET/CT in Oesophageal and Gastric Cancer. Springer, 2016.
Bischof Delaloye A, Chiti A, Dondi M, Goh A, Macapinlac HA, Mariani G, Rangarajan V, Stevens G. IAEA Human Health Series No. 9. International Atomic Energy Agency, 2010.
Macapinlac HA. Nuclear Medicine in Tumor Diagnosis and Therapy, Diagnostic Section. Churchill Livingston, 2004.

Letters to the Editor

Macapinlac, HA, Larson, SM. Whole body PET in oncology. Oncology 7: 52-55, 1993.

Less

CV information above last modified March 10, 2026

Homer A. Macapinlac, M.D., FACNM

About Dr. Homer A. Macapinlac

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson